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Amy Yoshiko Sato 
GLUCOCORTICOID INDUCED OSTEOPOROSIS AND  
MECHANISMS OF INTERVENTION  
Glucocorticoid excess is a leading cause of osteoporosis. The loss of bone mass 
and strength corresponds to the increase in fractures exhibited after three months of 
glucocorticoid therapy. Glucocorticoids induce the bone cellular responses of deceased 
bone formation, increased osteoblast/osteocyte apoptosis, and transient increased bone 
resorption, which result in rapid bone loss and degradation of bone microarchitecture.    
The current standard of care for osteoporosis is bisphosphonate treatment; 
however, these agents further suppress bone formation and increase osteonecrosis and 
low energy atypical fracture risks. Thus, there is an unmet need for interventions that 
protect from glucocorticoid therapy. The purpose of these studies was to investigate 
novel mechanisms that potentially interfere with glucocorticoid-induced bone loss. We 
chose to explore pathways that regulate endoplasmic reticulum stress, the canonical 
Wnt pathway, and Pyk2 activity. Pharmacologic reduction of endoplasmic reticulum 
stress through salubrinal administration protected against glucocorticoid-induced bone 
loss by preservation of bone formation and osteoblast/osteocyte viability. In contrast, 
inhibition of Wnt antagonist Sost/sclerostin and inhibition of Pyk2 signaling did not 
prevent glucocorticoid-induced reductions in bone formation; however, both 
Sost/sclerostin and Pyk2 deficiency protected against bone loss through inhibition of 
increases in resorption. Overall, these studies demonstrate the significant contributions 
of reductions in bone formation, increased osteoblast/osteocyte apoptosis, and 
elevations in resorption to the rapid 6-12% bone loss exhibited during the first year of 
glucocorticoid therapy.  
However, glucocorticoid excess also induces skeletal muscle weakness, which is 
not reversed by bisphosphonate treatment or the interventions reported here of 
vi 
salubrinal, Sost/sclerostin inhibition, or Pyk2 deficiency. Further, the novel finding of 
increased E3 ubiquitin ligase atrophy signaling induce by glucocorticoids in both bone 
and muscle, by tissue-specific upstream mechanisms, provides opportunities for 
therapeutic combination strategies. Thus, future studies are warranted to investigate the 
role of E3 ubiquitin ligase signaling in the deleterious glucocorticoid effects of bone and 
muscle. 
 
 
 
Teresita Bellido, Ph.D., Chair 
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Chapter 1 
Introduction 
Glucocorticoid-induced osteoporosis 
Excess of glucocorticoids (GC), either due to an endogenous elevation or due to 
administration as immunosuppressants, is one of the leading causes of increased bone 
fragility and osteoporosis worldwide (1;2). Glucocorticoids are secreted by the adrenal 
glands under the regulation of the hypothalamus-pituitary-adrenal (HPA) axis in 
response to biological stress and regulate numerous physiological processes such as 
carbohydrate and amino acid metabolism, maintenance of blood pressure, and 
modulation of stress and inflammatory responses (3-5). Glucocorticoid-induced 
osteoporosis was first described by Dr. Cushing as patients with endogenous elevation 
of GC, either due to Cushing’s disease or syndrome, exhibited an increased tendency 
for bone fractures (6).  Aging also leads to endogenous elevation of GC action with 
progressive increases in adrenal production of the hormone and increases in the 11β-
hydroxysteroid-dehydrogenase 1 (11β-HSD1) activity that favors conversion of inactive 
cortisone to active cortisol (7). The level of 11β-HSD1 activity is also highly predictive for 
the degree of bone formation suppression induced by GC, with higher 11β-HSD1 activity 
levels correlating to further reductions in circulating markers of bone formation (8). 
Administration of GC as immunosuppressant therapy is commonly prescribed for a wide 
range of conditions including rheumatoid arthritis, asthma, inflammatory bowel disease, 
lung diseases, chronic liver disease, skin diseases, multiple myeloma, and organ 
transplantation, resulting in long-term GC therapy with the consequent bone loss and 
fragility for many of these conditions (9;10).  
Excess of GC, from either endogenous or exogenous sources, leads to adverse 
effects in the musculoskeletal system as well as several other tissues and organs 
involving ocular, cardiovascular, nervous, and metabolic-related systems (5;10-14). For 
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instance, rapid increases in vertebral, hip, and nonvertebral (forearm) fracture risks have 
been reported as early as 3 months after initiation of systemic GC therapy with daily 
doses as low as 2.5 mg prednisolone (15). Glucocorticoid therapy induces loss of 
cortical and cancellous bone, reductions in bone strength, and atraumatic fractures for 
an estimated 30-50% of long-term therapy patients with the consequent morbidity and 
mortality (2;9;16-19). The GC deterioration of bone microarchitecture, through trabecular 
and cortical bone thinning, further contributes to the increased bone fragility, by 
precariously altering the threshold for fractures (20;21). Unfortunately, bone mineral 
density (BMD) assessments underestimate fracture risks of GC therapy patients as 
impaired bone microarchitecture cannot be detected by standard dual energy X-ray 
absorptiometry (DXA) measurements (20;22;23). In addition, GC induce muscle 
weakness, reduce body balance, and increase the prevalence of falls which when 
combined with lower bone mass greatly elevate the risk and occurrence of bone 
fractures (10;15;22).  
Biphasic nature of GC-induced bone loss 
GC induce osteoporosis by increasing bone resorption, decreasing bone 
formation, and increasing apoptosis of osteocytes and osteoblasts, resulting in bone 
fragility with elevated fracture risk, as indicated by human and animal models of GC 
excess (2;9;17-19;24-28). The initial phase of GC-induced bone disease involves a 
rapid, early bone loss with reports ranging from 6-12% losses during the first year of GC 
therapy (29). The rapid bone loss is attributed to increased resorption due to both a 
prolongation of preexisting osteoclast lifespan and increased osteoclastogenesis 
(24;30;31). Bone formation is also reduced in the initial phase (32) as GC downregulate 
the expression of OCN (33;34) and Col1A1 (35;36) resulting in decreased matrix mineral 
production. Prevalence of apoptotic osteoblasts and osteocytes is also elevated with GC 
administration, exhibited as early as 10 days after treatment in vivo (32). Overall, these 
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bone cellular responses to GC administration result in rapid bone loss with significant 
reductions in lumbar spine BMD occurring as early as 3 to 5 months with mean doses of 
7.5 mg/day prednisolone, with greater than 15 mg/day prednisolone doses considered 
typically as high doses (22;37;38).  
The initial phase of high bone resorption is followed by a low bone remodeling 
phase associated with reductions in both osteoclasts and osteoblasts numbers leading 
to chronic bone loss. The suppression of bone formation and increased 
osteoblast/osteocyte apoptosis continues throughout the chronic phase and the loss of 
these RANKL supporting cells has been attributed as the cause of reductions in 
resorption activity (9). The continuation of reduced bone formation corresponds with 
strong correlations between cumulative GC doses and reductions with BMD of the spine, 
hip, distal radius, and mid-radius as each consecutive year of GC therapy contributes to 
further bone loss (22).      
Current therapeutic anti-catabolic options 
 While several therapeutic options inhibit the resorption-driven bone loss by GC 
administration, these therapeutic options have undesirable side effects attributed to the 
severe reductions in bone turnover, without addressing bone formation reductions or 
muscle weakness pathology associated with glucocorticoid-induced osteoporosis (GIO).  
Currently, bisphosphonates are the standard of care for GIO and are widely-used 
anti-resorption agents for GIO internationally (2;10). Patients under immunosuppressant 
therapy and co-treated with the bisphosphonate alendronate exhibited higher BMD of 
the total body, lumbar spine, femoral-neck, and trochanter when compared to GC-
treated controls (14). Similar BMD conserving results have also been reported with 
administration of zoledronic acid or risedronate bisphosphonates in immunosuppressant 
therapy patients (39). However, while BMD is protected from resorption driven GC-
induced bone loss with bisphosphonates, the use of these agents significantly 
4 
suppresses bone turnover resulting in even further reductions of bone formation 
compared with GC treatment alone (14;32;40;41). Prolonged use of bisphosphonates is 
also associated with decreased bone tissue toughness, which increases the risk for low-
energy atypical fractures as the bone’s capacity to absorb energy before failure is 
diminished (42-44). Treatment with anti-RANKL antibodies in patients receiving GC 
induces even more pronounced reductions in bone formation, with roughly -30% lower 
circulating levels of N-terminal type I procollagen propeptide (P1NP) and OCN, when 
compared to treatment with bisphosphonates (45). The long-term prevention of 
resorption activity, whether due to bisphosphonate or anti-RANKL antibody 
administration, results in a loss of normal bone turnover which promotes microdamage 
and advanced glycation endproducts (AGEs) accumulation and increases risks for 
osteonecrosis of the jaw (42;43;46;47). Overall, these anti-catabolic agents preserve 
pre-existing bone to maintain BMD and lower fracture risk, but also further suppress the 
formation of new bone, which is not ideal for the GC chronic phase of bone loss or the 
long-term treatment nature of GC therapy.   
Current therapeutic anabolic agent 
 Currently, teriparatide, recombinant human parathyroid hormone (1-34), is the 
only FDA approved anabolic therapy. In contrast to anti-catabolic agents, that reduce 
bone formation to lower levels than GC treatment alone, teriparatide stimulates bone 
formation to increase BMD and lower fracture risks (40;48). The anabolic stimulation by 
teriparatide leads to the addition of new bone resulting in higher gains in BMD at critical 
bone sites of the lumbar spine (38;40;48), total hip (40;48), and femoral neck (48) than 
alendronate administration in GIO patients. The incidence of vertebral fractures is also 
significantly lower with teriparatide than alendronate therapy (40;48). Further, whereas 
circulating bone formation markers P1NP and bone alkaline phosphatase (ALP) as well 
as remodeling marker OCN are elevated with teriparatide, bisphosphonate 
5 
administration further reduced the levels of these circulating markers when compared to 
baseline GIO levels (40;48). However, currently there is a lack of long-term anabolic 
interventions as teriparatide therapy is only approved for 24 months in patients (49).  
Thus, understanding the mechanisms of GC action on the musculoskeletal 
system and identification the development of long-term therapeutic agents that prevent 
the detrimental side effects of anabolic bone suppression are imperative. The purpose of 
these studies was to investigate potential therapeutic targets for GC-induced skeletal 
effects within pathways regulating endoplasmic reticulum stress, canonical Wnt 
signaling, and Pyk2-induced apoptosis signaling. Future studies will investigate the role 
of E3 ubiquitin ligase signaling in the deleterious GC skeletal effects of bone and skeletal 
muscle.  
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Chapter 2 
Prevention of glucocorticoid induced-apoptosis of osteoblasts and osteocytes 
by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo 
in female mice 
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Introduction 
Excess of glucocorticoids (GC), either endogenous as in aging or due to 
glucocorticoid administration as immunosuppressants, leads to loss of bone (2). Chronic 
GC therapy is prescribed for a multitude of medical conditions including autoimmune 
diseases such as rheumatoid arthritis, organ transplants, asthma, as a component of 
cancer chemotherapies, and a variety of inflammatory afflictions (9;50). Patients with 
chronic GC exposure exhibit a consistent reduced bone formation rate and 
histomorphometric features of increased bone resorption (2;27;51). Studies with 
experimental animals in which GC action is blocked in osteoclasts or in 
osteoblasts/osteocytes support the notion that GC-induced bone loss occurs in two 
phases: an early bone loss caused by osteoclast-driven bone resorption, followed by a 
steady decline in both bone formation and bone resorption (26;30;52). Between 30 to 
50% of patients experience at least one bone fracture, with the consequent morbidity 
and mortality. Approximately 25% of patients also develop osteonecrosis due to 
accumulation of apoptotic osteocytes, which increases the risk of femoral head collapse 
(25). Thus, understanding the mechanisms of GC action on bone cells and designing 
therapeutic strategies that prevent the deleterious effects of these drugs are imperative. 
Increased apoptosis of osteoblasts and osteocytes is one of the mechanisms that 
underlie the reduced bone formation and bone fragility that characterize GC-induced 
osteoporosis (2). Apoptosis by GC is due to direct hormonal effects on osteoblasts and 
osteocytes (28;53;54) and is abolished by overexpressing in these cells the enzyme that 
inactivates GC, 11beta-hydroxysteroid dehydrogenase type 2 (26). The pro-apoptotic 
effects of GC are mediated through the classical GC receptor and are triggered by rapid 
activation of the kinases Pyk2 and JNK (54). GC-induced JNK phosphorylation lies 
downstream of increased reactive oxygen species (ROS) generation and subsequent 
activation of pro-apoptotic signaling in osteoblasts (55). Phosphorylation of eukaryotic 
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translation initiation factor 2α (eIF2α) by double-stranded RNA-activated protein kinase-
like ER kinase (PERK) protects cells from oxidative stress and apoptosis under ER 
stress conditions (56). Phosphorylated eIF2α slows global rate of protein translation to 
provide time for the ER to recover from the excessive protein load, allowing the cell to 
escape from apoptosis (56;57). Earlier findings showed that selective inhibition of eIF2α 
phosphatases with salubrinal or guanabenz protects from apoptosis induced by ER 
stress (58;59). Salubrinal increases the levels of phosphorylated eIF2α and protects 
PC12 pheochromocytoma cells from apoptosis induced by the ER stressor tunicamycin, 
in a dose dependent manner at concentrations varying from 1-100 μM (58). Further, 
guanabenz, another eIF2α phosphatase inhibitor, antagonizes the effect of tunicamycin 
on several cell types at concentrations up to 50 μM (59). We hypothesized that the pro-
apoptotic effect of GC on osteoblasts and osteocytes is at least in part due to induction 
of ER stress, and we investigated here whether the compounds salubrinal and 
guanabenz that inhibit eIF2α dephosphorylation will promote osteoblastic cell viability 
and oppose the deleterious effects of GC in vitro and in vivo.   
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Materials and Methods 
Cell lines. Primary osteoblastic cells were isolated from the neonatal calvarial 
bones of C57BL/6 mice, as previously published (60). Murine primary osteoblastic cells, 
bone marrow-derived OB-6 osteoblastic cells, and MLO-Y4 osteocytic cells were 
cultured as previously described (61;62).  
Quantification of cell detachment, apoptosis, and cell viability. Cell and nuclear 
morphology was quantified in MLO-Y4 osteocytic cells stably transfected with green 
fluorescent protein targeted to the nucleus (nGFP), as published (54). Briefly, cell 
detachment was assessed by quantifying the number of cytoplasmic processes per cell. 
Cells were then categorized into one of two groups: having 3 or less processes or having 
more than 3 processes; and data is reported as percentage of cells with 3 or less 
processes. Apoptosis was evaluated by quantifying the percentage of cells with 
chromatin condensation and nuclear fragmentation in the same cultures. Data is 
reported as percentage of apoptotic cells. 
Cells were treated with the anti-oxidant agents N-acetyl cysteine (NAC, 10 mM), 
ebselen (20 μM), or catalase (1250 U/ml), the eIF2α phosphatase inhibitors salubrinal 
(1-100 μM) and guanabenz (10 μM) (58;59), the bisphosphonate alendronate (0.1 μM), 
or corresponding vehicle (named control in the figures), for 1 hour. Subsequently, cells 
were exposed to the pro-apoptotic agents dexamethasone (1 μM), etoposide (50 μM), 
brefeldin A (2.7 μM), or tunicamycin (2.7 μM) or corresponding vehicle (named control in 
the figures), for the indicated times. Cell viability was assessed by trypan blue uptake as 
previously published (54;60). Cells that excluded the dye were considered alive, and 
stained cells were considered dead. Data is reported as the percentage of dead cells. 
Mineralization assay. Primary osteoblasts or OB-6 cells were plated at a density 
of 5000 cells/cm2 in growth medium consisting of MEM Alpha medium supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. Once cultures reached 
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confluence, medium was replaced by osteogenic medium containing 50 ug/ml ascorbic 
acid and 10 mM β-glycerophosphate together with 1 μM dexamethasone or its 
corresponding vehicle (ethanol), and 10 μM salubrinal or guanabenz or the 
corresponding vehicle (DMSO). Medium was replaced every 2-3 days. Mineralization 
was visualized using von Kossa phosphate staining (63), Alizarin Red S (Sigma-Aldrich) 
staining (64), or OsteoImage Mineralization Assay Kit (Lonza). Mineralization was 
quantified using a microplate reader for Alizarin Red S staining (405 nm absorbance) 
and Lonza staining (492/520 nm) excitation/emission fluorescence).  
In vivo study. C57BL/6 female mice (n=7-11 per group) were purchased from 
Harlan (Indianapolis, IN). After a 2 week acclimation period, four-month-old mice were 
implanted with 60 day slow-release pellets delivering placebo, 1.4 mg/kg/day (GC1) 
prednisolone, or 2.1 mg/kg/day (GC2) prednisolone (Innovative Research of America, 
Sarasota, FL) while under isoflurane anesthesia. For this, a small area between the 
shoulder blades was shaved and cleaned with 70% EtOH prior to incision. Daily 
subcutaneous injections of salubrinal (1 mg/kg/day, Tocris Bioscience, USA) or equal 
volume of vehicle (propylene glycol, Sigma Aldrich, named control) began 3 days prior to 
pellet implantation and continued until experiment termination. An additional group of 
GC2 implanted mice (n=10) received 5.25 mg/kg/week alendronate subcutaneous 
injections starting 3 days before pellet implantation. Mice were sacrificed 28 days after 
pellet implantation. Institutional Animal Care and Use Committee at Indiana University 
School of Medicine approved all animal procedures.  
Bone mineral density (BMD) measurements. BMD was determined in live mice 
by dual-energy x-ray absorptiometry (DXA) scanning using a PIXImus II densitometer 
(G.E. Medical Systems, Lunar Division, Madison, WI) (65). Experimental group 
assignment was randomized by basal spine BMD determined by DXA scanning 
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performed 5 days prior to pellet implantation. DXA scanning was also performed 28 days 
after pellet implantation.  
Bone histomorphometry and apoptosis. Distal femora were fixed in 10% neutral 
buffered formalin. After 48 hours in fixative, samples were transferred to 70% ethanol, 
and then embedded undecalcified in methyl methacrylate as previously described (28). 
Dynamic histomorphometry measurements were performed in 7-μm unstained bone 
sections under epifluorescence microscopy. For this purpose, 0.6% calcein and 1.0% 
alizarin red solutions were intraperitoneally injected 8 and 3 days prior to sacrifice. 
Histomorphometric analysis was performed with a computer and digitizer tablet 
(OsteoMetrics, Decatur, GA) interfaced to an Olympus BX51 fluorescence microscope 
(Olympus America Inc., Melville, NY) with a drawing tube attachment (66). Apoptotic 
cells were detected by transferase-mediated biotin-dUTP nick end-labeling (TUNEL) 
reaction in undecalcified longitudinal sections of the distal femur, as previously described 
(28). Analysis was performed in cancellous and cortical bone, starting 200 μm below the 
growth plate and ending at the mid-diaphysis.  
Statistical analysis. Data is expressed as means ± standard deviation (SD). 
Sample differences were assessed using SigmaPlot 12.0 (Systat Software Inc., San 
Jose, CA), following the appropriate method for each measurement, as indicated in the 
figure legends. Means were considered significantly different at p < 0.05.    
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Results 
Glucocorticoids induce apoptosis of osteocytic and osteoblastic cells by 
gernerating ROS. The synthetic glucocorticoid dexamethasone induced retraction of 
osteocytic MLO-Y4 cytoplasmic processes, an early sign of cell detachment that triggers 
apoptosis (anoikis) (54), as revealed by a reduction in the percentage of cells exhibiting 
3 or more cytoplasmic projections (Figure 2-1A). Dexamethasone also induced 
apoptosis of MLO-Y4 osteocytic cells, as quantified by evaluating chromatin 
condensation and nuclear fragmentation (Figure 2-1B and C). Further, dexamethasone 
increased the percentage of MLO-Y4 and OB-6 osteoblastic cells exhibiting trypan blue 
uptake (Figure 2-1D), another sign of apoptotic cell death induced by GC previously 
shown to be blocked by inhibiting caspase 3 activity (28;54;60). Pre-treatment with the 
anti-oxidants NAC, ebselen, or catalase prevented GC-induced apoptosis of either cell 
type, although for OB-6 cells the inhibitory effect of catalase was incomplete.  
Inhibition of eIF2α dephosphorylation with salubrinal and guanabenz prevents 
apoptosis induced by glucocorticoids, etoposide, and ER stressors in osteoblastic cells. 
Because ROS induce ER stress, we next investigated whether reduction of ER stress by 
inhibiting eIF2α dephosphorylation with salubrinal was able to prevent apoptosis induced 
by dexamethasone or etoposide, another pro-apoptotic stimulus that induces apoptosis 
by inhibiting topoisomerase II and DNA repair. Dexamethasone or etoposide consistently 
increased MLO-Y4 and OB-6 cell death (Figure 2-2). Salubrinal did not significantly 
affect cell viability, except for the increasing trypan blue uptake of MLO-Y4 cells at 100 
μM for 6 hours (Figure 2-2A). The mechanism behind the decreased viability induced by 
high concentrations of salubrinal is not known. However, it might be related to a transient 
increase in the expression of pro-apoptotic protein CHOP as found by Zhang et al. in 
MC3T3 osteoblastic cells (67). Further, 1-100 μM salubrinal prevented cell death 
induced by dexamethasone in both MLO-Y4 and OB-6 cells (Figure 2-2A and B). 
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Salubrinal also inhibited the effects of etoposide, but with less efficiency. The 10 μM 
salubrinal concentration was used for subsequent experiments as it consistently 
prevented dexamethasone-induced apoptosis in MLO-Y4 and OB-6 cells at both 6 and 
24 hour time points. Salubrinal and guanabenz, another inhibitor of eIF2α 
dephosphorylation, also inhibited apoptosis of OB-6 osteoblastic cells and primary 
osteoblasts induced by the inducers of ER stress brefeldin A, and inhibitor of the 
ER/Golgi apparatus vesicle transport, and tunicamycin, a protein glycosylation inhibitor 
(58) (Figures 2-3A-C). In contrast, alendronate, an agent previously shown to effectively 
inhibit apoptosis of osteocytic MLO-Y4 cells, osteoblastic OB-6 cells, and primary 
calvaria derived osteoblasts induced by dexamethasone or etoposide (28;65;68), was 
unable to prevent the increase in OB-6 cell death induced by the ER stress inducers 
(Figure 2-3B).  
Salubrinal and guanabenz ameliorate the inhibitory effects of glucocorticoids on 
matrix mineralization. We next investigated whether inhibitors of the ER stress alter the 
effects of GC on matrix mineralization. GC decreased mineral deposition in OB-6 
osteoblastic cells cultured under osteogenic conditions, as shown by staining with von 
Kossa (that detects phosphate) or Alizarin Red S (that detects calcium) (Figures 2-4A 
and B), or in primary osteoblasts measured by hydroxyapatite accumulation (Figure 2-
4C). Treatment with salubrinal or guanabenz increased mineralization of OB-6 cells 
(Figures 2-5A and B). Further, either compound partially prevented the decreased 
mineralization induced by GC in OB-6 or primary osteoblasts (Figure 2-5). Thus, 
salubrinal increased mineral content in cells treated with GC compared to GC alone after 
7 and 10 days of culture (Figure 2-5A). However, salubrinal treatment could not block 
GC reductions in mineralization after 14 days of GC exposure, but guanabenz remained 
effective throughout the two week GC treatment period (Figures 2-5A-C).  
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Salubrinal protects against osteoblast and osteocyte apoptosis in vivo and 
partially prevents the bone loss induced by glucocorticoids. We next investigated 
whether inhibition of eIF2α dephosphorylation promoted bone cell viability also in vivo. 
Guanabenz appeared to be more potent in opposing the in vitro effects of GC compared 
to salubrinal. However, guanabenz is also an α2 adrenergic receptor agonist used in the 
treatment of hypertension (69). To avoid potential skeletal effects of activating these 
receptors, we decided to use salubrinal for the in vivo study. C57BL/6 female mice 
implanted with pellets containing two different doses of the GC prednisolone (GC1 = 1.4 
or 2.1 mg/kg/day) received daily injections of salubrinal (1 mg/kg/day).  Mice treated with 
prednisolone exhibited increased apoptosis of osteoblasts in cancellous bone and of 
osteocytes in both cancellous and cortical bone (Figure 2-6). Salubrinal completely 
blocked GC1-induced apoptosis of both osteoblasts and osteocytes, whereas it only 
partially prevented the increase in GC2-induced apoptosis of osteoblasts and did not 
inhibit GC2-induced osteocyte apoptosis. On the other hand and consistent with 
previous findings (65), alendronate effectively prevented GC2-induced apoptosis of both 
osteoblasts and osteocytes in cancellous bone, although it did not inhibit GC2-induced 
cortical osteocyte apoptosis. Administration of prednisolone induced a significant 
decrease in BMD in total body, spine, and femur, at both doses compared to placebo 
(Figure 2-6B). Mice implanted with placebo pellets and treated with salubrinal lost 
significantly less spinal BMD compared to those treated with vehicle. Similarly, mice 
implanted with GC1 pellets and injected with salubrinal lost significantly less bone 
compared to mice implanted with GC1 pellets and injected with vehicle. On the other 
hand, salubrinal did not prevent the loss of bone induced by GC2. In contrast, inhibition 
of resorption with alendronate not only prevented GC2-induced bone loss, as previously 
shown (65), but also increased BMD over placebo treated mice. Moreover, GC1 and 
GC2 reduced bone formation rate (BFR) in cancellous bone by a combination of 
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reduction in MS/BS and in MAR (Figure 2-6C). Salubrinal reversed the decreased BFR 
induced by GC1 but not GC2. Alendronate reduced further GC2-mediated inhibition of 
BFR by decreasing both MS/BS and MAR.  
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Discussion 
 Apoptosis of osteoblasts and osteocytes contributes to the reduced bone 
formation and increased bone fragility in glucocorticoid-induced osteoporosis (25;26;52). 
Therefore, understanding the mechanisms by which GC induce apoptosis of osteoblastic 
cells is critical for the development of intervention therapies. Earlier studies 
demonstrated that apoptosis of osteocytes and osteoblasts is caused by loss of 
attachment to the extracellular matrix mediated by inside-out signaling down-stream of 
Pyk2/JNK kinases (54) and that GC increase ROS production in bone in vivo and in 
osteoblastic cells in vitro (55). We investigated in this study the effect on GC action of 
salubrinal and guanabenz, eIF2α dephosphorylation inhibitors that block ROS-induced 
ER stress (58;59). These compounds prevented the pro-apoptotic effect of GC on 
osteoblasts and osteocytes in vitro and the decrease in mineral deposition induced by 
GC in osteoblastic cell cultures.  Further, salubrinal prevented apoptosis of osteoblasts 
and osteocytes induced by GC in vivo and the concomitant decrease in bone mass and 
bone formation.  
 Consistent with the current study demonstrating inhibition of apoptosis of 
osteoblasts and osteocytes and improved mineralization by decreasing ER stress, 
recent evidence demonstrates increased apoptosis of osteoblastic cells and changes in 
osteoblast differentiation associated with elevated ER stress in vitro with thapsigargin or 
tunicamycin (70;71). Remarkably, increased ER stress appears to have a time-
dependent biphasic effect inducing rapid increase in osteoblast markers Runx2 and 
osterix, followed by a reduction in the expression of these transcription factors as well as 
osteocalcin (70). Further, ER stress-mediated apoptosis of osteoblasts and impaired 
osteoblast differentiation was also demonstrated in a model of osteogenesis imperfecta 
(72) and in mice lacking the ER-localization protein Arl6ip5 in osteoblasts (73). 
Consistent with the pro-apoptotic and inhibitory effect of ER stress on osteoblast 
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differentiation, in the current manuscript we show that opposing ER stress by inhibiting 
eIF2α dephosphorylation prevents osteoblast and osteocyte apoptosis and the decrease 
in osteoblast function induced by GC in vitro and in vivo. Our findings agree with 
previous evidence showing that salubrinal increases the number of alkaline phosphatase 
positive colonies in bone marrow cell cultures (74) and osteocalcin expression in 
MC3T3-E1 cells (75).  
 In contrast to the protective effect of salubrinal against the action of low GC dose 
(GC1), salubrinal was unable to protect the skeleton from the high GC dose (GC2). 
Similarly, whereas salubrinal or guanabenz effectively prevented the inhibition of 
mineralization induced by short-term treatment of cultured osteoblasts with GC, only 
guanabenz was able to reverse the effects of prolonged treatment with GC. The 
mechanism of the different outcome of guanabenz compared to salubrinal is not known. 
It remains unclear also the reason for the incomplete inhibition of cortical osteocyte 
apoptosis by alendronate in this experiment, since in earlier studies alendronate 
completely prevented apoptosis of osteoblastic cells in both cancellous and cortical bone 
(65). A potential explanation is that in the previous study alendronate was administered 
daily instead of in a weekly 7-day cumulative dose. Nevertheless, these findings suggest 
that the potency of the pro-apoptotic signals delivered by GC, either due to high dose or 
prolonged exposure, determines the ability of the protective compound to induced 
survival and that once a pro-apoptotic threshold is reached, salubrinal is not able to 
reverse it.   
 Consistent with the in vitro and in vivo data showing that inhibition of eIF2α 
dephosphorylation preserves osteoblast viability, treatment with salubrinal reversed the 
inhibition in BFR induced by low dose of GC mainly by reversing the decrease in MS/BS. 
These findings together with the demonstration that salubrinal prevents the reduction in 
mineralization induced by GC in vitro strongly suggest that the preservation of bone 
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mineral density by salubrinal is due to its protective effects on osteoblasts. In contrast, 
alendronate further reduced BFR in GC treated animals, as expected due to its potent 
inhibitory effects on osteoclasts and resorption. Salubrinal, like alendronate, has been 
also shown to inhibit osteoclastogenesis (75) and to protect from ovariectomy-induced 
bone loss (76). However, in the setting of GC excess, the main mechanism of salubrinal 
action appears to be related to osteoblasts. Thus, the bone sparing actions of salubrinal 
and bisphosphonates on GC excess are mediated by distinct cellular mechanisms. 
Whereas alendronate inhibits osteoclast activity and reduces bone turnover, salubrinal 
preserves the viability and the bone forming function of osteoblasts.  
 Protein misfolding is a common feature of several human diseases including 
neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases, as well as 
type 2 diabetes (77). Lack of functional PERK, the sensor of the unfolded protein 
response and a major eIF2α kinase, causes the Wolcott-Rallison syndrome (WRS) in 
humans, which characterized by early onset diabetes and aberrant skeletal development 
(78). PERK deletion in the mouse prevents the unfolded protein response induced by ER 
stressors and inhibits phosphorylation of eIF2α (79). Homozygous PERK null mice are 
born normal but loose β cells rapidly and develop early diabetes (80). As with WRS 
patients, PERK knockout mice develop skeletal dysplasia and defective bone 
mineralization (81). Osteoblast and osteocyte number, mineral apposition rate MAR, and 
markers of osteoblasts and osteocytes are decreased in PERK null mice. Osteoblast 
survival appears not to be affected in vitro, albeit in vivo studies were not shown. 
Together with the current study in which increased osteoblast and osteocyte apoptosis, 
decreased bone formation, and decreased bone mass induced by glucocorticoids are 
partially prevented by salubrinal, these findings suggest that inhibition of eIF2α 
dephosphorylation is a potential novel target for the treatment of glucocorticoid-induced 
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osteoporosis and other conditions with deficient osteoblast differentiation and bone 
mineralization.  
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Figure 2-1. Glucocorticoid-induced apoptosis of osteocytic and osteoblastic cells 
is prevented by inhibiting ROS generation. (A-D) Cells were exposed to vehicle 
(ethanol) or dexamethasone for 6 hours. (A) Quantification of cytoplasmic retraction in 
stably transfected nGFP MLO-Y4 cells treated with or without NAC for 1 hour prior to 
addition of dexamethasone. (B) Apoptosis quantification of nGFP-transfected MLO-Y4 
cells. (C) Representative images of nGFP-expressing MLO-Y4 osteocytic cells treated 
with vehicle or dexamethasone showing changes in cell morphology, chromatin 
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condensation, and nuclear fragmentation. Lines correspond to 200 μm. (D) 
Quantification of cell death in MLO-Y4 osteocytic or OB-6 osteoblastic cells with or 
without pretreatment of the indicated anti-oxidant agent, assessed by trypan blue 
uptake. Bars represent the means ± SD of N=3 independent wells/treatment. *p<0.05 vs. 
the corresponding vehicle-treated cells, by one-way ANOVA.  
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Figure 2-2. Protection against ER stress with salubrinal prevents dexamethasone 
and etoposide induced apoptosis of osteocytic MLO-Y4 and osteoblastic OB-6 
cells. Cell death quantification in MLO-Y4 osteocytic (A) or OB-6 osteoblastic (B) cells 
treated with or without salubrinal prior to addition of vehicle, dexamethasone, or 
etoposide, assessed by trypan blue uptake. Bars represent the means ± SD of N=3 
samples per treatment.  *p<0.05 vs. cells treated with vehicle without salubrinal and 
#p<0.05 vs. corresponding apoptotic agent without salubrinal for each time point, by 
one-way ANOVA.  
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Figure 2-3. Salubrinal or guanabenz protects from apoptosis induced by 
dexamethasone, etoposide, and ER stressors in osteoblastic cells. Cell death 
quantification in OB-6 osteoblastic (A and B) or primary osteoblastic (C) cells treated 
with or without anti-apoptotic agents salubrinal, alendronate, or guanabenz prior to 
addition of dexamethasone (dex), etoposide (etop), brefeldin A (breA), tunicamycin (tm), 
or vehicle (veh). Bars represent the means ± SD of N=3 samples per group.  *p<0.05 vs. 
veh-treated cells and #p<0.05 vs. corresponding apoptotic agent without designated 
eIF2α phosphatase inhibitor for each time point, by Student’s t-test in (A) and (C) and by 
one-way ANOVA in (B).  
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Figure 2-4. Glucocorticoid decreases matrix mineralization in cultures of 
osteoblastic cells and primary osteoblasts. (A and B) OB-6 osteoblastic cells 
cultured with or without dexamethasone (dex) and the degree of mineralization was 
assessed by von Kossa staining for 8 days (A) and by Alizarin Red S staining for 1 or 2 
weeks (B). (C) Calvaria-derived osteoblastic cells were cultured with or without 
osteogenic medium for 1 or 2 weeks together with vehicle (veh) or dexamethasone (dex) 
and mineralization was assessed using the OsteoImage Mineralization Assay Kit. Lines 
correspond to 200 μm. Bars represent the means ± SD of N=3 for (A) and (B), N=6 for 
(C) samples per group.  *p<0.05 vs. veh-treated cells in corresponding medium condition 
for each time point, by two-way ANOVA.  
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Figure 2-5. Salubrinal and guanabenz ameliorate the inhibitory effects of GC on 
matrix mineralization. (A) Mineralization was determined in vehicle (veh) or 
dexamethasone (dex) treated differentiated OB-6 cells without (control) or with salubrinal 
(sal) pre-treatment for 7, 10, and 14, days by Alizarin Red S staining. (B) and (C) 
quantification of mineralization in OB-6 (B) and calvaria-derived (C) osteoblastic cells 
treated with vehicle or dexamethasone with or without guanabenz (gz) for the indicated 
incubation periods. Hydroxyapatite accumulation was measured by OsteoImage 
Mineralization Assay Kit. Lines correspond to 400 μm. Bars represent the means ± SD of 
N=3 for (A) and N=12 for (B-C). *p<0.05 vs. veh-treated control cells and #p<0.05 vs. 
dex-treated control cells, by one-way ANOVA.  
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Figure 2-6. Salubrinal protects against glucocorticoid-induced apoptosis and 
consequent bone loss in vivo. (A) TUNEL and (C) dynamic histomorphometric data 
was obtained from longitudinal distal femur sections. Representative images of 
fluorochrome labeled bones are shown. Bars correspond to 50 μm. (B) BMD percent 
changes for placebo, 1.4 mg/kg/day prednisolone (GC1), or 2.1 mg/kg/day prednisolone 
(GC2) pellet implanted mice with or without salubrinal intervention were determined by 
DXA analysis. Bars represent the means ± SD of N=7-10 for (A) and (C) and N=6-10 for 
(B). Statistical analysis for placebo, GC1, and GC2 treated mice treated with vehicle 
(control) or salubrinal was performed by two-way ANOVA. *p<0.05 vs. placebo mice 
injected with vehicle (control) or salubrinal. #p<0.05 vs. corresponding GC treated mice 
injected with vehicle (control). The effect of alendronate on GC2 treated mice was 
analyzed by comparing placebo, GC2, and GC2 plus alendronate by one-way ANOVA. 
*p<0.05 vs. placebo mice injected with vehicle (control) and #p<0.05 vs. GC2 treated 
mice injected with vehicle (control).  
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Chapter 3 
Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling 
in the absence of Sost/sclerostin 
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Introduction 
Excess of glucocorticoids, either endogenously or iatrogenically-induced, leads to 
loss of bone and is one of the leading causes of increased bone fragility worldwide (82).  
Glucocorticoids, produced and released by the adrenal glands in response to biological 
stress, regulate numerous physiological processes in a wide range of tissues (3;4). 
Exaggerated production of glucocorticoids is found in patients with pituitary tumors 
producing adrenocorticotrophin hormone (ACTH) (Cushing’s disease), or exhibiting 
Cushing’s syndrome due to ectopic ACTH production or autonomous adrenal production 
of cortisol. Further, glucocorticoid action progressively increases with age due to 
elevated hormonal adrenal secretion as well as conversion of inactive to active 
metabolites catalyzed by 11β-hydroxysteroid-dehydrogenase 1 in target tissues. In 
addition, glucocorticoids are extensively used for the treatment of immune and 
inflammatory conditions including rheumatoid arthritis, for the management of organ 
transplantation, and as components of chemotherapy regimens for hematological 
cancers including multiple myeloma. Both endogenous and pharmacologic increase in 
glucocorticoid levels are associated with severe adverse side effects manifested in 
several tissues and organs, in particular the skeleton (10-14). Prolonged treatment with 
glucocorticoids leads to a dramatic loss of bone mineral and strength in cortical and 
cancellous bone, and increases atraumatic fractures in approximately 30-50% of 
patients (2;9;16-19). Excess glucocorticoids also causes muscle weakness with the 
consequent loss of body balance and increased falls, which in turn contribute to elevate 
the risk of bone fractures (10). It is estimated that 4.4 million individuals in United States 
and United Kingdom are chronically treated with oral glucocorticoids (10;83) and the use 
of these agents extends worldwide.  
Human and animal studies demonstrate that the mechanism of glucocorticoid-
induced osteoporosis involves increased bone resorption, decreased bone formation, 
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and increased apoptosis of osteocytes and osteoblasts, which together contribute to 
bone weakness and elevated fracture risk (2;9;17-19;24-28). There is a rapid, early bone 
loss ascribed to both prolongation of life span of preexisting osteoclast and increased 
generation of new osteoclasts (24;30;31). This initial phase is followed by a less 
pronounced chronic bone loss associated with reduction of osteoblasts and osteoclasts 
and low bone remodeling, due to reduced synthetic activity of osteoblasts through 
downregulation of critical genes, including osteocalcin (OCN), increased osteoblast 
apoptosis, and reduced generation of osteoclasts resulting from the loss of supporting 
cells (2;9;82).  
The Wnt/β-catenin pathway has a critical role in the control of bone acquisition 
and maintenance. Wnt/β-catenin signaling is activated by ligands of the Wnt family that 
bind to frizzled receptors and co-receptors, and also by downregulation of antagonists, 
including Dkk1 and Sost/sclerostin (84). Human mutations responsible for high bone 
mass conditions, including gain-of-function of the LRP5 Wnt co-receptor 
(OMIM603506.0013), loss of expression of the Sost/sclerostin inhibitor in Van Buchem 
disease (OMIM239100) and sclerosteosis type 1 (OMIM269500), and loss-of-function of 
the sclerostin chaperone LRP4 in sclerosteosis type 2 (OMIM614305), demonstrate that 
activation of the Wnt/β-catenin pathway is linked to increased bone formation and bone 
gain (85-87). In addition, genetic manipulation of β-catenin, the mediator of the canonical 
Wnt pathway, affects bone resorption due to regulation of the expression of 
osteoprotegerin (OPG), the decoy receptor for RANKL, receptor activator of nuclear 
factor kappa B ligand, demonstrating that this pathway is also linked to resorption 
(88;89). Therefore, the Wnt/β-catenin signaling cascade can regulate bone mass by both 
bone anabolic and anti-catabolic mechanisms. Further, activation of Wnt/β-catenin 
signaling promotes osteoblast and osteocyte survival (90). Based on these pieces of 
evidence, we investigated whether activation of Wnt/β-catenin signaling in female mice 
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lacking Sost/sclerostin opposes glucocorticoid-induced loss of bone mineral and 
strength, and examined the cellular and molecular mechanisms involved.  
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Materials and Methods 
Mice and tissue procurement. Four-month-old female Sost-/- mice of C57BL/6 
background generated by Li et al. 2008 (91) or wild type (WT) littermate controls, 10 
mice per group, were implanted with 90 day slow-release pellets delivering placebo, 1.4 
mg/kg/day (GC1), or 2.1 mg/kg/day (GC2) prednisolone (Innovative Research of 
America) while under anesthesia. Previous studies showed that these doses reproduce 
in the mouse the hallmarks of glucocorticoid-induced osteoporosis and are equivalent to 
medium and high therapeutic glucocorticoid doses in humans (41;52). Moreover, the 
C57BL/6 mouse is a reliable and reproducible model for glucocorticoid-induced skeletal 
deterioration, as demonstrated by consistent decreases in BMD, reduction in bone 
formation, and increased osteoblast/osteocyte apoptosis (26;41).  Mice were injected 10 
and 3 days prior to sacrifice with 0.6% calcein and 1.0% alizarin red solutions, 
respectively. Twenty-eight days after pellet implantation mice were sacrificed. Bones and 
muscles were dissected. Bones were processed as indicated below. Wet weight of 
indicated muscles from both hind limbs was taken and averaged for each mouse. 
Analysis was performed in a blinded fashion.   
BMD measurement and micro-CT analysis. BMD of the total body excluding the 
head and the tail, the lumbar spine (L1-L6), and the femur, and lean body mass were 
measured by dual energy X-ray absorptiometry (DXA) scanning by using a PIXImus II 
densitometer (G.E. Medical System, Lunar Division). Body weight and DXA 
measurements were performed 2-4 days before (initial) and 28 days (final) after pellet 
implantation (65;92). Mice were randomized to the experimental groups based on spine 
BMD. Percent changes in body weight, lean body mass, and BMD were calculated with 
the following formula: [(final–initial)/initial] multiplied by 100.  
For micro-CT analysis, L6 vertebrae were cleaned of soft tissue, fixed in 10% 
buffered formalin, and stored in 70% ethanol until scanned at 6-μm resolution (Skyscan 
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1172, SkyScan). Measurements were done 60 µm away from the growth plates as 
previously described (93;94).  
Serum biochemistry. Blood was collected 2 and 4 weeks after pellet implantation 
from the facial vein of 3-hour fasted mice. N-terminal propeptide of type I procollagen 
(P1NP), C-terminal telopeptides of type I collagen (CTX), and tartrate-resistant acid 
phosphatase form 5b (TRAP 5b) were measured using enzyme-linked immunosorbent 
assays (Immunodiagnostic Systems Inc.) (32;92). Alkaline phosphatase was measured 
on a Randox Daytona analyzer (Randox Laboratories Limited).  
Quantitative PCR (qPCR). Total RNA extraction and qPCR  were performed as 
previously reported (95). Briefly, total RNA was extracted from lumbar vertebrae L5, 
femur, ex vivo cultured bones, using TRIzol (Invitrogen). cDNA was synthesized by 
using high capacity cDNA reverse transcriptase kit (Applied Biosystems). Gene 
expression was analyzed using primer probe sets from Applied Biosystems or from 
Roche Applied Science. Relative mRNA expression levels were normalized to the 
housekeeping gene ribosomal protein S2 (Rplp2) by using the ΔCt method (94;95).  
Data are expressed as fold change, where the ratio between the gene of interest and the 
housekeeping gene for WT mice receiving placebo was considered as 1.   
Bone histomorphometry and apoptosis analysis. L1-3 vertebrae were fixed in 
10% neutral buffered formalin and embedded undecalcified in methyl methacrylate as 
previously described (28). Dynamic histomorphometry measurements were performed in 
7-μm unstained bone sections under epifluorescence microscopy. Histomorphometric 
analysis was performed using OsteoMeasure high resolution digital video system 
(OsteoMetrics) interfaced to an Olympus BX51 fluorescence microscope (Olympus 
America Inc.) (66). Osteoclasts were quantified on lumbar vertebra L2 thin sections 
stained for tartrate-resistant acid phosphatase (TRAP) and counterstained with Toluidine 
Blue as previously published (32;92). An osteoclast was defined as a TRAP positive cell 
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attached to the bone surface with more than 1 nucleus. Apoptosis of osteoblasts and 
osteocytes was detected by the transferase-mediated biotin-dUTP nick end-labeling 
(TUNEL) reaction (Fisher) in undecalcified vertebral bone sections counterstained with 
2% methyl green, mounted on silane-coated glass slides (Scientific Device Lab, Inc.), as 
previously described (28). The prevalence of apoptotic osteoblasts and osteocytes was 
calculated by enumerating the total number and TUNEL positive cells exhibiting 
condense chromatin, nuclear fragmentation or cell shrinkage.   
Immunohistochemistry. The expression of sclerostin was visualized in paraffin-
embedded femora from 5 month-old WT and Sost-/- mice 28 days after pellet 
implantation, as previously described (93;96). Sclerostin was visualized in deparaffinized 
sections of decalcified femora, treated with 3% H2O2 to inhibit endogenous peroxidase 
activity, blocked with serum, and then incubated with goat polyclonal anti-mouse 
sclerostin antibody (1:100; Abcam, catalog Ab63097) (92).  Sections were then 
incubated with anti-goat biotinylated secondary antibody followed by avidin conjugated 
peroxidase (Vectastain Elite ABC Kit; Vectora Laboratories, catalog PK-6105). Color 
was developed with a diaminobenzidine substrate chromogen system (Dako Corp.). 
Cells expressing the protein of interest are stained in brown, whereas negative cells are 
green-blue.  
Mechanical testing. Mechanical properties of L6 vertebrae were determined by 
axial compression after removal of vertebral processes and the cranial and caudal 
endplates. Vertebral bodies were loaded at a rate of 0.5 mm/min until failure (100P225 
Modular Test Machine) as previously described (97;98). Structural properties were 
obtained from the load/displacement curves and material-level properties were 
calculated using published equations to normalize to vertebral height, cross-sectional 
area, and bone volume (46).  
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Ex vivo cultures. Femoral and tibial long bones were harvested from WT and 
Sost-/- mice, and then maintained in α-MEM containing 10% FBS and 1% 
penicillin/streptomycin for 24 hours. Bones were treated with 1 μM dexamethasone or 
vehicle (ethanol) with or without an anti-sclerostin antibody (99) (10μg/mL; Acris 
Antibodies, catalog AP13235PU-N) or vehicle (PBS) for 6 hours. mRNA was isolated 
and gene expression was measured by qPCR, as indicated above.    
Mineralization assay. Primary osteoblastic cells were isolated from the neonatal 
calvarial bones of C57BL/6 mice, Sost-/-, or WT littermate control mice, and plated at 
5000 cells/cm2 density in MEM Alpha medium with 10% fetal bovine serum and 1% 
penicillin/streptomycin as previously described (41;60). Osteogenic medium was used 
after cultures reached confluence consisting of 50μg/ml ascorbic acid and 10mM β-
glycerophosphate and treated with 1μM dexamethasone or the corresponding vehicle 
(ethanol).  Medium was replaced every 2-3 days, and mineralization was visualized 
using the OsteoImage Mineralization Assay Kit (Lonza), and then quantified by 
microplate reader for 492/520 nm excitation/emission fluorescence.     
Statistical analysis. Data are expressed as means ± standard deviations (SD). 
Sample differences were evaluated using SigmaPlot 12.0 (Systat Software Inc.). Data of 
the in vivo experiments were analyzed by two-way ANOVA using genotype and 
treatment as independent variables. When ANOVA detected a significant interaction 
between the variables or a significant main effect of genotype, a post-hoc test was used 
to determine the significance of the effect of the treatment within each genotype. The 
only exception was the analysis of the mechanical testing data in which one-way 
ANOVA for each genotype using treatment as independent variable was used, because 
the marked differences between WT and Sost-/- mice in these parameters precluded the 
detection of the effect of glucocorticoids when two-way ANOVA was used. All Pairwise 
Multiple Comparison Procedures within one- or two-Way ANOVA tests using the Tukey 
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method were utilized to detect genotype and/or treatment differences. Results of the 
ANOVA and post-hoc test are presented in the Supplementary Information online at 
jbmr2869-sup-0001-SuppData-S1.docx. Data of the in vitro experiments were analyzed 
by two-tailed Student’s t-test. Data of the ex vivo experiments, in which bones from each 
leg of the same mouse were treated with vehicle or dexamethasone, were analyzed by 
paired t-test. Means were considered significantly different at p<0.05.  
Study approval.  All animal procedures were approved by the Institutional Animal 
Care and Use Committee of Indiana University School of Medicine, and animal care was 
carried out in accordance with institutional guidelines. 
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Results 
Sost-/- mice are protected from bone loss and decreased bone strength induced 
by glucocorticoids, but not from the loss of muscle mass. Mice lacking the osteocyte-
derived antagonist of Wnt/β-catenin signaling Sost/sclerostin (Sost-/- mice) displayed 
high bone mass and strength compared to wild type (WT) littermate controls (Figure 3-
1), consistent with earlier reports (91). Glucocorticoid administration at two different 
doses of prednisolone (GC1=1.4 or GC2=2.1 mg/kg/day) significantly decreased total 
and spinal BMD (Figure 3-1A), cancellous bone trabecular thickness (Tb.Th.), cortical 
bone area (BA/TA) in lumbar vertebra of WT mice (Figure 3-1B and C), although no 
changes in cancellous BV/TV were detected. The high GC does also decreased cortical 
thickness (Ct.Th.). The decreased thickness of cortical bone was driven by thinning of 
the dorsal surface. Glucocorticoid excess also reduced the mechanical properties of WT 
bones, at both the structural level (ultimate force and energy to ultimate load) and at the 
material level (toughness), although modulus and ultimate stress were not altered 
(Figure 3-1D). In contrast, Sost-/- mice were protected from glucocorticoid-induced 
decrease in bone mass, changes in bone architecture in cancellous and cortical sites, as 
well as the reduction in bone strength (Figure 3-1).  Ultimate stress is an estimate of the 
strength of the material – calculated as ultimate force normalized by the amount of bone. 
Therefore, the lack of changes in ultimate stress by glucocorticoids in either genotype 
indicates that the decrease in ultimate force is driven by structural changes as opposed 
to changes in tissue properties (such as mineralization or collagen alterations).  
The protection from loss of tissue mass by Sost/sclerostin deficiency was specific 
to bone, since Sost-/- mice exhibited glucocorticoid-induced sarcopenia similar to WT 
mice (Figure 3-2). Thus, both WT and Sost-/- mice treated with prednisolone displayed 
decreased lean body mass, an index of skeletal muscle mass, with a loss of 6-9% in 
lean body mass over the 4 week-treatment (Figure 3-2A). In addition, the weight of the 
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fast twitch type II dominated muscles from glucocorticoid-treated mice of both genotypes 
was equally decreased about 22-23% and 13-15% for gastrocnemius and tibialis 
anterior, respectively (Figure 3-2B). On the other hand, glucocorticoids did not decrease 
in either genotype the weight of the slow twitch type I dominated soleus muscle, a 
muscle type shown to be less sensitive to the action of the hormones (100). These 
changes in bone and muscle mass induced by glucocorticoids occurred in the absence 
of alterations in total mouse body weight (Figure 3-2C). 
Sost/sclerostin deficiency does not prevent glucocorticoid-induced decrease in 
bone formation, increase in osteoblast/osteocyte apoptosis, or reduced mineral 
deposition. Consistent with the recognized bone anabolism induced by Wnt/β-catenin 
activation, Sost-/- mice exhibited increased bone formation indexes at the tissue level 
(mineralizing surface, MS/BS; mineral apposition rate, MAR; and bone formation rate, 
BFR/BS) and in the circulation (procollagen type 1 N terminal propeptide, P1NP; and 
alkaline phosphatase, ALP); as well as increased mRNA expression in bone of the 
osteoblast marker osteocalcin, OCN (Figure 3-3A-D).  
In spite of the elevated bone formation exhibited by the Sost deficient mice under 
basal conditions, glucocorticoids decreased MAR and BFR/BS to a similar extent 
compared to placebo in WT and Sost-/- mice (Figure 3-3A). Specifically, BFR/BS was 
reduced by about 30-40% in both WT and Sost-/- mice. Further, circulating P1NP and 
ALP were decreased by glucocorticoids in both genotypes at 2 weeks (Figure 3-3B and 
C). In addition, glucocorticoids reduced P1NP in the Sost-/- mice. In addition, 
glucocorticoids markedly decreased OCN expression in bones from both WT and Sost-/- 
mice (Figure 3-3D). Further, both WT and Sost-/- mice receiving prednisolone exhibited 
high prevalence of osteoblast and osteocyte apoptosis in cancellous and cortical bone 
(Figure 3-3E), consistent with the relationship between decreased bone formation and 
promotion of osteoblast (and osteocyte) apoptosis by glucocorticoids (26;28;52). 
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Moreover, addition of the glucocorticoid dexamethasone to cultured primary calvarial 
osteoblasts decreased mineral deposition in cells isolated from WT or Sost-/- mice 
(Figure 3-3F).  
Sost/sclerostin deficiency prevents glucocorticoid-induced increase in bone 
resorption. Sost-/- mice exhibited overall unremarkable changes in osteoclasts and 
resorption compared to WT mice under basal conditions (Figure 3-4). Compared to WT 
mice, Sost deficient mice showed no differences in osteoclast surface (Oc.S/BS), blood 
bone resorption marker C-terminal telopeptide fragments of type I collagen (CTX) at 4 
weeks or osteoclast marker tartrate-resistant acid phosphatase 5b (TRAP5b) at 2 and 4 
weeks; and only a minor decrease in osteoclast number (N.Oc/BS) at 4 weeks and a 
transient increase in CTX at 2 weeks. Further, glucocorticoids increased osteoclast 
number (N.Oc/BS) and surface (Oc.S/BS) and raised CTX and TRAP5b circulating 
levels in WT mice. In contrast, glucocorticoids failed to do so at any dose or time point in 
Sost-/- mice.  
Glucocorticoids differentially alter the anti-catabolic versus anabolic/survival 
molecular signature of the Wnt/β-catenin pathway in a Sost/sclerostin-dependent 
manner. Treatment with glucocorticoids increased Sost mRNA and the prevalence of 
sclerostin positive osteocytes in WT mice; and, as expected, Sost or sclerostin 
expression was not detectable in bones from Sost-/- mice (Figure 3-5A and B). 
Consistent with the recognized antagonistic function of Sost/sclerostin on Wnt/β-catenin 
activation, glucocorticoids decreased the expression of several target genes of the 
pathway, including OPG, Cx43, BMP4, cyclin D1, Axin2, and Smad6 in WT mice (Figure 
3-5C). However, glucocorticoids only decreased the expression of a set of these genes 
in Sost-/- mice, suggesting that sustained activation of Wnt/β-catenin signaling due to 
Sost/sclerostin deficiency only partially opposes glucocorticoid effects on gene 
expression. Overall, similar patterns of expression were found in bones from the 
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appendicular (femur) and axial (lumbar vertebra) skeleton. Specifically, glucocorticoids 
decreased the expression of cyclin D1, Smad6, and Axin2 in both WT and Sost-/- mice. 
In contrast, they decrease the expression of OPG, Cx43, and BMP4 only in WT mice. 
Increased cyclin D1 is associated with bone anabolism and anti-apoptosis (94;101-103); 
and increased OPG is responsible for inhibition of osteoclast formation and resorption 
(88;89;104). Thus, whereas glucocorticoids oppose all Wnt/β-catenin signaling in the 
presence of Sost/sclerostin, the hormones only oppose signaling associated with bone 
formation/survival in the absence of Sost/sclerostin.  
Genetic or pharmacologic activation of Wnt/β-catenin signaling blocks 
downregulation of OPG expression induced by glucocorticoids.  The lack of 
downregulation of OPG in Sost-/- mice (Figure 3-5C) resulted in lower RANKL/OPG ratio 
in prednisolone-treated Sost-/- mice compared to WT mice (Figure 3-6A). The differential 
regulation of OPG in WT and Sost-/- mice was due to direct action of glucocorticoids on 
osteocytes as evidenced in ex vivo cultures of bones enriched in osteocytes. Genetic 
deletion of Sost or pharmacologic inhibition of sclerostin with the neutralizing antibody in 
ex vivo bone organ cultures mimicked the in vivo regulation of OPG in Sost-/- mice. Thus, 
glucocorticoids increased Sost and decreased OPG expression, resulting in increased 
RANKL/OPG ratio in cultured bones from WT mice (Figure 3-6B and C). In contrast, 
bones from Sost-/- mice were protected from glucocorticoid-induced decrease in OPG 
and increase in RANKL/OPG ratio (Figure 3-6B). Similarly, glucocorticoids failed to 
decrease OPG and increase the RANKL/OPG ratio in WT bones in which sclerostin 
function was blocked with an anti-sclerostin antibody (Scl-Ab), even when Sost mRNA 
expression was still increased by glucocorticoids (Figure 3-6C). RANKL expression was 
not consistently regulated by glucocorticoids either in vivo or ex vivo (Figure 3-6), 
demonstrating that OPG expression is responsible for the differential regulation of the 
RANKL/OPG ratio observed in the presence or absence of Sost/sclerostin deficiency. 
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Discussion 
Glucocorticoid-induced osteoporosis is a leading cause of bone fragility 
worldwide and better therapies are critically needed. This study provides insights into 
novel mechanisms of glucocorticoid action and the cellular and molecular basis by which 
activation of Wnt/β-catenin signaling interferes with the detrimental effect of 
glucocorticoid excess in bone, but not in muscle, using in vivo, ex vivo, and in vitro 
approaches.  
We report that glucocorticoids hinder the expression of target genes of the 
Wnt/β-catenin pathway, regardless of whether they are associated with bone anabolism 
(i.e. bone gain) or anti-catabolism (i.e. inhibition of bone loss). Glucocorticoids exert this 
action, in part, by increasing the expression of Sost/sclerostin, the osteocyte-derived 
Wnt/β-catenin antagonist and potent inhibitor of bone formation. Future investigations 
are warranted to determine whether this phenomenon is due to direct regulation of 
transcription of the Sost gene or whether is exerted through indirect mechanisms. 
Nevertheless, Sost/sclerostin deficiency protected against the loss of bone mass, 
deterioration of microarchitecture, and reduction of extrinsic/structural and 
intrinsic/material mechanical properties induced by glucocorticoids. Remarkably, 
however, the bone protective effect of Sost/sclerostin deficiency against glucocorticoids 
was not due to an opposing action to increase bone formation and maintain anabolic 
signaling. Instead, it was due to preservation of the Wnt/β-catenin anti-catabolic cellular 
and molecular signature (Figure 3-7). These results indicate that a pathway 
predominantly anabolic for bone is switched to anti-catabolic in the frame of 
glucocorticoid excess. Our findings suggest that therapeutic interventions activating 
Wnt/β-catenin signaling could effectively halt the high bone resorption responsible for the 
profound and rapid bone loss induced by glucocorticoids, which in humans can reach up 
to 12% during the first year of treatment (2).   
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Consistent with our current findings in skeletally mature Sost/sclerostin deficient 
mice, previous studies showed that pharmacologic inhibition of sclerostin with a 
neutralizing antibody opposed the lack of bone gain and the loss of strength induced by 
glucocorticoids in growing mice (105;106). Although it was proposed that these effects 
were due to preservation of osteoblast activity (106), mice treated with glucocorticoids 
and the anti-sclerostin antibody in these earlier studies exhibited lower circulating TRAP 
5b (105) or CTX-1 (106), but still markedly reduced bone formation markers osteocalcin 
and P1NP (105), compared to the corresponding mice treated with glucocorticoids 
alone. Likewise, our in vivo studies show that sustained activation of the Wnt/β-catenin 
signaling in Sost deficient mice abolishes the increase in resorption induced by 
glucocorticoids but not the decreased bone formation. Moreover, our ex vivo results 
demonstrate that glucocorticoids are unable to decrease OPG and increase the 
RANKL/OPG ratio in bones from Sost-/- mice or in WT bones treated with an anti-
sclerostin antibody. Taking together, these findings demonstrate that Sost/sclerostin 
deficiency, either genetic or pharmacologically achieved with the neutralizing anti-
sclerostin antibody, maintains bone mass and strength in conditions of glucocorticoid 
excess by inhibiting bone resorption, through sustained anti-catabolic signaling driven by 
OPG.   
In our mouse model of glucocorticoid-induced osteoporosis, the bone loss in this 
early phase is accompanied by both decreased bone formation and increased bone 
resorption, with the latter being the only one opposed by Sost/sclerostin deficiency. In 
view of the striking reduction in bone formation that remains in both genotypes, we 
speculate that during the second phase of glucocorticoid-induced osteoporosis that 
occurs with prolonged treatment and that is driven by reduced bone formation, bone loss 
could occur even in the Sost KO mice. Future investigations are warranted to address 
this issue. 
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Although bone mass, shape, and microarchitecture are the major recognized 
contributors to bone strength, accumulating evidence supports also an important role of 
osteocyte viability (26;32;107). Our findings demonstrate that Sost KO mice treated with 
glucocorticoids maintain structural and material mechanical properties despite of 
increased osteocyte apoptosis, highlighting the relative contribution of these factors. 
Evidently, the high bone mass and strong architecture exhibited by the Sost KO mice 
compensate for the bone weakening effects of increased osteocyte apoptosis under 
glucocorticoid excess. 
A clinical case reported that glucocorticoids stop the exaggerated bone gain and 
reduced the high circulating P1NP in a patient with Van Buchem disease, a condition 
that results from lack of sclerostin expression and in which continuous bone anabolism 
causes life-threatening increased intracranial pressure (108). Prior to glucocorticoid 
intervention, the patient exhibited annual BMD gains of 4 to 9% in the lumbar spine and 
of 4 to 24% in the hip. Treatment with prednisone blunted the anabolic effect of Sost 
deficiency as evidenced by no gain in BMD after two years (-0.7% in lumbar spine and 
0.4% in the hip). Our report showing that bone formation and Wnt/β-catenin anabolic 
signaling is still decreased in Sost/sclerostin deficient mice treated with glucocorticoids 
provides a mechanistic explanation for these clinical findings. Taken together with the 
current study, these pieces of evidence demonstrate that glucocorticoids oppose the 
effects of Sost/sclerostin deficiency on bone formation in both humans and mice.  
Inhibition of resorption with bisphosphonates is the current standard of care for 
glucocorticoid-induced osteoporosis (2;10). These drugs protect from the loss of bone 
mass induced by glucocorticoids in animal models and patients. However, bone 
formation is decreased even further by bisphosphonates compared to glucocorticoids 
alone (14;32;40;41). Treatment with anti-RANKL antibodies induces even more 
pronounced reductions in bone formation compared to treatment with bisphosphonates 
47 
in patients receiving glucocorticoids (45). Profound reduction in bone turnover is not 
desirable since it leads to accumulation of microdamage and advanced glycation 
endproducts (AGEs), and the potential for developing osteonecrosis of the jaw with long-
term treatments (42;43;46;47). Severe suppression of turnover by bisphosphonates can 
also lead to reduced toughness (42-44), the energy that bone tissue absorbs before 
failure, which in turn could be the cause of increased risk for low-energy atypical 
fractures (109;110). In contrast to purely antiresorptive agents, Sost deficiency confers 
high bone formation per se; thus, Sost deficient mice treated with glucocorticoids exhibit 
bone formation levels comparable to WT mice treated with placebo. Even when the 
reduction in P1NP induced by glucocorticoids in Sost KO mice is more severe than in 
WT mice, the reduced P1NP is similar to that of placebo-treated WT mice (Figure 3B). 
Similarly, the reduced bone formation exhibited by Sost KO mice treated with 
glucocorticoids is equivalent to bone formation in placebo-treated WT mice (Figure 3A).  
These findings suggest that Sost/sclerostin deficiency maintains tissue-level toughness 
by preserving modest amounts of bone formation while preventing glucocorticoid-
induced increases in resorption. This mechanical finding points to a potential benefit 
compared to the current therapeutic approach to treat glucocorticoid-induced bone 
fragility.  
Another unwanted consequence of excess glucocorticoids, either endogenous or 
iatrogenic, is muscle weakness; which reduces body balance and, when combined with 
lower bone mass, increases the risk of bone fractures. Due to their intimate association 
as a mechanical unit, changes in bone might impact skeletal muscle and vice versa. Our 
mouse model of glucocorticoid elevation faithfully reproduces the bone and skeletal 
muscle atrophy exhibited by humans. However, the bone preservation resulting from 
Sost/sclerostin deficiency in our studies did not protect from muscle atrophy; and 
conversely, the marked loss of muscle mass experienced by the Sost deficient mice did 
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not translate into apparent detrimental effects on bone volume or mechanical properties. 
These findings demonstrate that Sost/sclerostin deficiency protects exclusively bone, but 
not muscle, from the action of glucocorticoids, and show a lack of crosstalk between 
these two tissues in the frame of glucocorticoid-induced musculoskeletal atrophy. Future 
studies are warranted to investigate whether muscle-derived factors contribute to the low 
bone formation and high prevalence of osteoblast and osteocyte apoptosis still exhibited 
by Sost/sclerostin deficient mice treated with glucocorticoids. Nevertheless, more recent 
findings of ours showed that glucocorticoids induce bone and muscle atrophy by distinct 
mechanisms upstream of the atrophy-related E3 ligases atrogin1 and MuRF1 (111). 
Taken together with the current study, these findings support the contention that 
combination of bone- and muscle-specific therapeutic interventions might be required to 
interfere with the damaging actions of glucocorticoids in the musculoskeletal system.  
We demonstrate that glucocorticoids differentially regulate anabolic/survival 
versus anti-catabolic Wnt/β-catenin signaling depending on the expression of 
Sost/sclerostin. Thus, whereas cyclin D1 is downregulated and bone formation is 
inhibited regardless of whether Sost is expressed or not, the decrease in OPG and 
increase in bone resorption is strictly dependent on Sost expression. The basis for this 
differential regulation of Wnt/β-catenin target genes by glucocorticoids remains 
unknown. However, glucocorticoids might regulate some of these genes by interfering 
with the Wnt/β-catenin pathway itself, whereas they might control other genes either 
directly by repressing the activity of their promoters or through regulation of alternative 
pathways including kinase signaling or induction of ROS/endoplasmic reticulum (ER) 
stress (41;54;55;103;112;113).  
In closing, the current report demonstrates that the deleterious effects of 
glucocorticoids on the skeleton are linked to increased expression of the osteocyte-
derived Wnt/β-catenin antagonist Sost/sclerostin and to downregulation of Wnt/β-catenin 
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target genes; and that Sost/sclerostin deficiency prevents glucocorticoid-induced 
osteoporosis by anti-catabolic, not anabolic, actions. 
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Figure 3-1. Sost-/- mice are protected from bone loss and decreased bone strength 
induced by glucocorticoids. (A) Percent change in BMD for WT or Sost-/- mice treated 
with placebo, 1.4 mg/kg/d prednisolone (GC1), or 2.1 mg/kg/d prednisolone (GC2) for 28 
days, measured by DXA. N=7-10. (B) Representative reconstructed micro-CT images of 
L6 vertebral cancellous bone (3D, top row) and cortical bone (2D, lower row). The dorsal 
surface of cortical bone for which thickness was also quantified is indicated by the gray 
boxes. (C) Bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th.), 
separation (Tb.Sp.), and number (Tb.N.), cortical bone area/total area (BA/TA), 
thickness of cortical bone (total Ct.Th.), and thickness of the dorsal surface of cortical 
bone (dorsal Ct. Th.) are shown. N=7-10. (D) Biomechanical properties were measured 
in vertebral bone (L6) by axial compression testing; N=6-9. Bars represent means ± SD. 
*p<0.05 vs. corresponding placebo-treated mice and #p<0.05 vs. placebo-treated WT 
mice, by two-way ANOVA; §p<0.05 vs. corresponding placebo-treated mice by one-way 
ANOVA, Tukey post-hoc test. 
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Figure 3-2. Sost/sclerostin deficiency does not prevent glucocorticoid-induced 
sarcopenia. Final and percent change in lean body mass (A), the mass of the indicated 
muscles (B), and final and percent change in total body weight (C) are shown; N=8-10. 
Bars represent means ± SD. *p<0.05 vs. corresponding placebo-treated mice and 
#p<0.05 vs. placebo-treated WT mice by two-way ANOVA, Tukey post-hoc test. 
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Figure 3-3. Sost/sclerostin deficiency does not prevent glucocorticoid-induced 
decrease in bone formation or increase in osteoblast/osteocyte apoptosis. (A) 
Representative images of fluorochrome incorporation and dynamic histomorphometric 
data measured in longitudinal sections of lumbar vertebra (L1-L3). Mineralizing bone 
surface per bone surface (MS/BS), mineral apposition rate (MAR), and bone formation 
rate per bone surface (BFR/BS) are shown. Scale bars: 50 μm, N=8-10. P1NP, N=6-10 
(B), and alkaline phosphatase, N=7-10 (C) were measured in blood collected 2 or 4 
weeks after pellet implantation. (D) Osteocalcin (OCN) gene expression was quantified 
by qPCR in L5 lumbar vertebra and femur. N=7-10 for WT and N=6-8 for Sost-/- mice. 
mRNA levels were normalized to the housekeeping gene ribosomal protein large P2 
(Rplp2). (E) Apoptosis of osteoblasts (Ob) and osteocytes (Ot) was quantified in 
cancellous and cortical bone in longitudinal sections of lumbar vertebrae (L1-L3) stained 
for TUNEL. N=6. Representative images of cortical bone are shown. Scale bar: 20 µm. 
(F) Quantification of mineralization in cultures of calvaria-derived primary osteoblastic 
cells from WT or Sost-/- mice treated with vehicle (veh) or dexamethasone (dex) for 1 or 
2 weeks stained using the OsteoImage Mineralization Assay Kit (RFU 492nm/520nm 
excitation/emission fluorescence). Scale bars: 400 μm. N=7-8. Bars represent means ± 
SD. (A-E) *p<0.05 vs. corresponding placebo-treated mice and #p<0.05 vs. placebo-
treated WT mice by two-way ANOVA, Tukey post-hoc test. (F) *p<0.05 vs. 
corresponding vehicle-treated primary osteoblasts by Student’s t-test. 
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Figure 3-4. Sost-/- mice are protected from the increase in bone resorption induced 
by glucocorticoid. (A) Representative microscopy images of osteoclasts on cancellous 
bone surface in lumbar vertebra (L2) stained for TRAPase. Osteoclast number 
(N.Oc/BS) and surface (Oc.S/BS) normalized to bone surface were measured. Scale 
bars: 30 μm, N=5. CTX, N=6-11 (B) and TRAP 5b, N=6-7 (C) were measured in blood 
collected 2 and 4 weeks after pellet implantation. Bars represent means ± SD. *p<0.05 
vs. corresponding placebo-treated mice and #p<0.05 vs. placebo-treated WT mice by 
two-way ANOVA, Tukey post-hoc test. 
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Figure 3-5. Glucocorticoids differentially alter Wnt/β-catenin signaling in a 
Sost/sclerostin-dependent manner. (A) Sost gene expression was quantified by qPCR 
in L5 lumbar vertebra. N=7-10 for WT and N=6-8 for Sost-/-. (B) The percentage of 
sclerostin positive osteocytes was quantified in longitudinal sections of femoral bone 
stained with an anti-sclerostin antibody and is shown as percentage ± SD shown, N=3-4. 
Scale bars: 50 μm. (C) Expression of the indicated genes normalized to the 
housekeeping gene Rplp2 in femur and lumbar vertebra (L5). N= 7-10 for WT and N= 6-
8 for Sost-/-. Bars represent means ± SD. *p<0.05 vs. corresponding placebo-treated 
mice and #p<0.05 vs. placebo-treated WT mice by two-way ANOVA and Tukey post-hoc 
test. §p<0.05 vs. placebo-treated WT mice, by one-way ANOVA and the Tukey post-hoc 
test. 
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Figure 3-6. Genetic or pharmacologic inhibition of Sost/sclerostin blocks 
downregulation of OPG expression and the increase in RANKL/OPG ratio induced 
by glucocorticoid. (A) Expression of the indicated genes normalized to the 
housekeeping gene Rplp2 in femur and lumbar vertebra (L5). N= 7-10 for WT and N= 6-
8 for Sost-/-. *p<0.05 vs. corresponding placebo-treated mice and #p<0.05 vs. WT mice 
treated with the same glucocorticoid dose by two-way ANOVA, Tukey post-hoc test. (B 
and C) Gene expression in bones from WT or Sost-/- mice, N=6 (B) or from WT mice 
cultured with or without anti-sclerostin antibody (Scl-Ab), N=16 (C) were treated ex vivo 
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with vehicle or dexamethasone for 6 hours. *p<0.05 vs. corresponding vehicle-treated 
bones, by paired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7. Sost/sclerostin deficiency prevents glucocorticoid-induced bone loss. 
Glucocorticoid-induced osteoporosis is characterized by decreased bone formation, 
increased apoptosis of osteocytes (Ot) and osteoblasts (Ob), and increased osteoclasts 
(Oc) and bone resorption, which combined induced bone loss and fragility. Activation of 
Wnt/β-catenin signaling resulting from Sost/sclerostin deletion protects from 
glucocorticoid-osteoporosis by inhibiting bone resorption through sustained anti-
catabolic signaling driven by osteoprotegerin, OPG.  
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Chapter 4 
Pyk2 deficiency protects from glucocorticoid-induced bone resorption and 
osteoblast and osteocyte apoptosis, but not from the decrease in bone formation 
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In this study, we demonstrate that Pyk2 deficiency prevents the bone loss and 
weakening effects of glucocorticoids in vivo due to a lack of GC-induced bone 
resorption. Pyk2 KO mice were also protected from glucocorticoid-induced apoptosis of 
osteoblasts and osteocytes; however, the glucocorticoid-induced suppression of bone 
formation occurred independently of Pyk2 expression and activity. To our knowledge, 
this is the first report demonstrating that Pyk2 deficiency leads to increased prevalence 
of osteoclast apoptosis, and inhibition of Pyk2 blocks the anti-apoptotic effects of 
glucocorticoids on osteoclasts.  
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Introduction 
 Glucocorticoid excess is the leading iatrogenic cause of osteoporosis world-wide 
and the third cause of osteoporosis overall, and novel therapeutic interventions are 
sorely needed (2). Glucocorticoid administration as immunosuppressant therapy is 
commonly used for a wide range of conditions, such as rheumatoid arthritis, asthma, 
inflammatory bowel disease, lung diseases, chronic liver disease, skin diseases, 
myeloma, and organ transplantation (9;10). However, glucocorticoids have direct, 
detrimental effects on the skeleton, resulting in bone fractures for an estimated 30-50% 
of long-term glucocorticoid-treated patients (2;10;22;27;114). Further, the bone loss and 
microarchitectural thinning of trabecular bone all contribute to the increased bone 
fragility and fracture risks associated with glucocorticoid administration.      
Glucocorticoid-induced bone loss is accompanied by increased prevalence of 
osteoblast and osteocyte apoptosis, decreased formation, and increased resorption. 
Glucocorticoids lead to the phosphorylation of proline-rich tyrosine kinase 2 (Pyk2) in 
MLO-Y4 osteocytic cells, and silencing Pyk2 or expression of a kinase inactive Pyk2 
prevents GC-induced apoptosis (54). Thus, the pro-apoptotic glucocorticoid effect on 
osteocytic cells requires Pyk2 expression and function in vitro (54). Another study 
showed that Pyk2 KO mice, as well as rats treated with a Pyk2 kinase inhibitor, also 
exhibit increased bone formation (115). Moreover, work from the Baron and 
Schlessinger groups reported that Pyk2 KO mice exhibit high bone volume and 
increased osteoclasts, which exhibit disorganized podosomes and impaired attachment 
to dentin in vitro (116). Collectively, this evidence raises the possibility that Pyk2 is 
involved in the effects of glucocorticoids on bone cells. The purpose of the current study 
was to investigate whether Pyk2 is required for the bone loss induced by glucocorticoids, 
and if so by which cellular mechanism, by interfering with resorption, apoptosis, or 
formation.      
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Materials and Methods 
Mice and tissue procurement. Four-month-old female Pyk2-/- mice of C57BL/6 
background generated by Okigaki et al. 2003 (117) or wild type (WT) littermate controls, 
10 mice per group, were implanted with 90 day slow-release pellets delivering placebo, 
1.4 mg/kg/day (GC1), or 2.1 mg/kg/day (GC2) prednisolone (Innovative Research of 
America) while under anesthesia. Mice were injected 10 and 3 days prior to sacrifice 
with 0.6% calcein and 1.0% alizarin red solutions, respectively. Twenty-eight days after 
pellet implantation mice were sacrificed. Bones were dissected and processed as 
indicated below. Analysis was performed in a blinded fashion.   
BMD measurement and micro-CT analysis. BMD of the total body excluding the 
head and the tail, the lumbar spine (L1-L6), and the femur, and lean body mass were 
measured by dual energy X-ray absorptiometry (DXA) scanning by using a PIXImus II 
densitometer (G.E. Medical System, Lunar Division). DXA measurements were 
performed 2-4 days before (initial) and 28 days (final) after pellet implantation (65;92). 
Mice were randomized to the experimental groups based on initial spine BMD. Percent 
changes in BMD were calculated with the following formula: [(final–initial)/initial] 
multiplied by 100.  
For micro-CT analysis, L6 vertebrae were cleaned of soft tissue, fixed in 10% 
buffered formalin, and stored in 70% ethanol until scanned at 6-μm resolution (Skyscan 
1172, SkyScan). Measurements were done 60 µm away from the growth plates as 
previously described (93;94).  
Mechanical testing. Mechanical properties of L6 vertebrae were determined by 
axial compression after removal of vertebral processes and the cranial and caudal 
endplates. Vertebral bodies were loaded at a rate of 0.5 mm/min until failure (100P225 
Modular Test Machine) as previously described (97;98). Structural properties were 
obtained from the load/displacement curves and material-level properties were 
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calculated using published equations to normalize to vertebral height, cross-sectional 
area, and bone volume (46). 
Serum biochemistry.  Blood was collected 2 and 4 weeks after pellet implantation 
from the facial vein of 3-hour fasted mice. N-terminal propeptide of type I procollagen 
(P1NP), C-terminal telopeptides of type I collagen (CTX), and tartrate-resistant acid 
phosphatase form 5b (TRAP 5b) were measured using enzyme-linked immunosorbent 
assays (Immunodiagnostic Systems Inc.) (32;92). Osteocalcin was measured using the 
Mouse Osteocalcin KIA Kit (Biomedical Technologies Inc.).   
Bone histomorphometry and apoptosis analysis. L1-3 vertebrae were fixed in 
10% neutral buffered formalin and embedded undecalcified in methyl methacrylate as 
previously described (28). Dynamic histomorphometry measurements were performed in 
7-μm unstained bone sections under epifluorescence microscopy. Histomorphometric 
analysis was performed using OsteoMeasure high resolution digital video system 
(OsteoMetrics) interfaced to an Olympus BX51 fluorescence microscope (Olympus 
America Inc.) (66). Osteoclasts were quantified on lumbar vertebra L2 thin sections 
stained for tartrate-resistant acid phosphatase (TRAP) and counterstained with Toluidine 
Blue as previously published (32;92). An osteoclast was defined as a TRAP positive cell 
attached to the bone surface with more than 1 nucleus. A marrow osteoclast was 
defined as TRAP positive cells with 2 or more nuclei separated from the bone surface by 
at least one cell.  
Apoptosis of osteoblasts and osteocytes was detected by the transferase-
mediated biotin-dUTP nick end-labeling (TUNEL) reaction (Fisher) in undecalcified 
vertebral bone sections counterstained with 2% methyl green, mounted on silane-coated 
glass slides (Scientific Device Lab, Inc.), as previously described (28). Apoptosis of 
osteoclasts and marrow osteoclasts was detected in double stained TRAPase, to identify 
osteoclasts, and TUNEL, to identify apoptotic cells, in paraffin-embedded femora from 5-
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month-old WT and Pyk2-/- mice 28 days after pellet implantation. The prevalence of 
apoptotic osteoblasts, osteocytes, osteoclasts, and marrow osteoclasts was calculated 
by enumerating the total number of TUNEL positive cells exhibiting condense chromatin, 
nuclear fragmentation, or cell shrinkage.    
Mineralization assay. Primary osteoblastic cells were isolated from the neonatal 
calvarial bones of C57BL/6 mice, Pyk2-/-, or WT littermate control mice, and plated at 
5000 cells/cm2 density in MEM Alpha medium with 10% fetal bovine serum and 1% 
penicillin/streptomycin as previously described (41;60). Osteogenic medium was used 
after cultures reached confluence consisting of 50 μg/ml ascorbic acid and 10 mM β-
glycerophosphate and treated with 1 μM dexamethasone or the corresponding vehicle 
(ethanol), and Pyk2 inhibitor (PF-431396) or the corresponding vehicle (DMSO). Medium 
was replaced every 2-3 days, and mineralization was visualized using the OsteoImage 
Mineralization Assay Kit (Lonza) or Alizarin Red S (Sigma-Aldrich) staining (41).  
Mineralization was quantified using a microplate reader for Lonza staining (492/520 nm 
excitation/emission fluorescence) or for Alizarin Red S staining (405 nm absorbance) 
(41).     
Osteoclast apoptosis assay in vitro. Primary bone marrow cells were flushed with 
sterile PBS from tibiae and femora of C57BL/6 mice or WT and Pyk2-/- mice and cultured 
in MEM Alpha medium with 10% fetal bovine serum and 1% penicillin/streptomycin for 
48 hours, as previously described (24). Nonadherent cells were collected, re-plated at 
300,000 cells/cm2 density, and differentiated with 80 ng/ml recombinant murine soluble 
RANKL (PeproTech) and 20 ng/ml recombinant murine M-CSF (PeproTech) for 4-6 
days. Medium was replaced every 2 days and cells were treated with 10-5M alendronate 
or corresponding vehicle (PBS) one hour prior to 1 μM dexamethasone or the 
corresponding vehicle (EtOH) addition. After 24 hours, cells were fixed with 10% 
buffered formalin, rinsed with dH2O, and stained for TRAPase (Sigma-Aldrich) with 
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hematoxylin counterstaining. Apoptotic osteoclasts were identified by the presence of 
morphologic characteristics such as the loss of cell membrane integrity, nuclear 
condensation, and fragmentation. 
Statistical analysis. Data are expressed as means ± standard deviations (SD). 
Sample differences were evaluated using SigmaPlot 12.0 (Systat Software Inc.). Data of 
the in vivo and in vitro experiments were analyzed by two-way ANOVA using genotype 
and treatment as independent variables. When ANOVA detected a significant interaction 
between the variables or a significant main effect of genotype, the post-hoc test Tukey 
was used to determine the significance of the effect of the treatment within each 
genotype.  
Study approval.  All animal procedures were approved by the Institutional Animal 
Care and Use Committee of Indiana University School of Medicine, and animal care was 
carried out in accordance with institutional guidelines. 
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Results 
Pyk2 deficiency protects from GC-induced bone loss and reductions in bone 
strength. Mice lacking Pyk2 displayed high bone mass at all sites (Figure 4-1A) when 
compared to wild type (WT) littermate controls. Pyk2-/- mice also exhibited increased 
cancellous bone (BV/TV), trabecular thickness, trabecular number, and decreased 
trabecular separation (Figure 4-1B). Both doses of prednisolone (GC1=1.4 or GC2=2.1 
mg/kg/day) significantly decreased total, spine, and femur BMD in WT mice (Figure 4-
1A). GC-induced a significant loss of cancellous BV/TV bone at the high dose and the 
characteristic trabecular thinning at both doses in WT mice (Figure 4-1B). In contrast, 
Pyk2 deficient mice were resistant to these effects, as reductions in BMD, cancellous 
bone, or trabecular thickness did not occur in GC treated Pyk2-/- mice. 
Pyk2-/- vertebral bones also exhibited increased structural mechanical properties 
of ultimate force, energy to ultimate load, and stiffness (Figure 4-1C) when compared to 
WT vertebral bones. However, no differences in material properties were detected 
between the two genotypes of placebo treated mice, which indicates that the gains in 
bone strength of Pyk2-/- mice is due to structural changes and not tissue level alterations 
(i.e. mineralization or collagen alterations). Both doses of GC reduced the ultimate force, 
energy to ultimate load, and toughness of vertebral bones from WT mice, with exception 
for the low GC dose regarding ultimate force. In contrast, bones from Pyk2-/- mice were 
protected from these GC-induced bone weakening effects.      
Pyk2 deficiency protects from osteoblast and osteocyte apoptosis, but not the 
suppression of bone formation or mineral deposition induced by GC. Consistent with the 
previously published in vitro results showing that GC-induced apoptosis of MLO-Y4 
osteocytic cells requires Pyk2 kinase expression and activity (54), GC increased the 
prevalence of osteoblast and osteocyte apoptosis in cancellous bone and of osteocyte 
apoptosis in cortical bone in WT mice, but not in Pyk2 KO mice (Figure 4-2A). These 
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findings demonstrate that Pyk2 deficiency protects from osteoblast and osteocyte 
apoptosis induced by GC also in vivo. In contrast, GC reduced serum levels of bone 
formation marker P1NP and of OCN at both doses in WT as well as in Pyk2 KO mice 
(Figure 4-2B). Further, GC decreased bone formation indexes to the same extent in WT 
and in Pyk2 KO mice with decreases of MS/BS, MAR, and BFR (Figure 4-2C). GC 
treatment also decreased hydroxyapatite deposition in vitro in osteoblast cultures from 
both WT and Pyk2 KO mice (Figure 4-2E). Interestingly, mineral deposition was 
increased in cultures of Pyk2 KO osteoblasts or WT osteoblasts treated with .02 μM 
Pyk2 kinase inhibitor (Figure 4-2E-F) in the absence of GC, resembling the increased 
bone formation in the femur reported by Buckbinder et al. 2007 (115). As a dose 
response toxicity effect was exhibited with 2 μM or higher Pyk2 kinase inhibitor 
concentrations (Figure 4-2F), doses of .02 and .2 μM were selected for following 
experiments. Similarly to the Pyk2 KO in vivo and in vitro results, GC also decreased 
calcium deposition in the absence or presence of the Pyk2 kinase inhibitor PF-431396. 
Thus, GC-induced suppression of bone formation or mineral deposition does not require 
Pyk2 expression or activity. 
Pyk2 deficiency protects from GC-induced bone resorption. Both doses of GC 
induced the expected increases in serum CTX, an index of bone resorption, and in 
TRAP 5b, an index of osteoclast number, of WT mice (Figure 4-3A-B). In contrast, GC 
failed to increase serum CTX in Pyk2 KO mice. TRAP 5b was already elevated in Pyk2 
KO mice, and GC did not further increase TRAP 5b circulating levels. Consistently with 
the mismatch between CTX and TRAP 5b the ratio of CTX/TRAP 5b, an index of the 
activity of individual osteoclasts, was reduced in Pyk2 KO mice (Figure 4-3C). 
Moreover, GC did not change the CTX/TRAP 5b ratio in WT mice, indicating that the 
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increase in resorption in WT mice was due to an increase in osteoclast number, and not 
due to an increase in osteoclast activity.  
GC increased osteoclast number in bone of WT as well as of Pyk2 KO mice 
(Figure 4-3D). Remarkably however, GC increased osteoclast surface only in WT mice 
and not in Pyk2 KO mice. Close examination of the bone sections showed that whereas 
osteoclasts in WT treated with GC were attached to the bone, osteoclasts in Pyk2 KO 
mice treated with GC were not completely attached to bone (Figure 4-3E-F). This 
phenomenon explains the mismatch between osteoclast number and surface, and is 
consistent with the reduced CTX/TRAP 5b found in the circulation of Pyk2 KO mice. 
Moreover, compared to WT bones, Pyk2 KO bones exhibited more than double number 
of osteoclasts in the bone marrow (Figure 4-3D). Marrow osteoclasts were identified as 
TRAP positive cells with 2 or more nuclei, separated from the bone surface by at least 
one cell. Thus, Pyk2 deficiency protects from the increase in osteoclast surface induced 
by GC. 
Pyk2 deficient mice exhibit increased osteoclast apoptosis, which is not altered 
by GC. We next explored the possibility that the osteoclasts from the Pyk2 KO mice that 
exhibit impaired attachment to bone were undergoing premature death by apoptosis. 
Bone sections were double stained with TRAPase to identify osteoclasts and TUNEL to 
identify apoptotic cells. High magnification images show a living osteoclast in WT bone 
and an apoptotic, TUNEL positive osteoclasts in Pyk2 KO bone (Figure 4-4A). 
Quantification of TUNEL and TRAPase double stained osteoclasts revealed that Pyk2 
KO bones exhibited increased prevalence of apoptotic osteoclasts on bone surfaces as 
well as osteoclasts in the bone marrow when compared to WT controls. The increase in 
osteoclast apoptosis induced by Pyk2 deficiency was not altered by GC treatment. 
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Taken together these findings demonstrate that impaired attachment in osteoclasts 
lacking Pyk2 leads to apoptosis.  
Consistent with previous reports (116), Pyk2 deficient osteoclasts also exhibited 
abnormal morphology with the absence of organized podosome belt structures and 
impaired osteoclast spreading (Figure 4-4B). Also, osteoclasts derived from Pyk2 KO 
mice exhibited approximately 95% reduction in the number of TRAP positive cells with 3 
or more nuclei when compared to WT derived osteoclasts, which led to the quantification 
of TRAP positive cells with less than 3 nuclei for Pyk2 deficient osteoclasts.  
As previously shown (24), the bisphosphonate alendronate increased apoptosis 
of mature osteoclasts generated in vitro with RANKL and MCSF for 5 days from marrow 
precursors of WT mice (Figure 4-4B). Normal osteoclasts show intact cell membrane, 
TRAPase staining evenly distributed in the cytoplasm, and round nuclei. Apoptotic 
osteoclasts exhibited the characteristic features of apoptotic cells, i.e. loss of cell 
membrane integrity, nuclear condensation and fragmentation, and the TRAPase staining 
is condensed in darker areas. Consistent with previous published reports (24), addition 
of dexamethasone partially prevented apoptosis induced by the bisphosphonate 
alendronate of osteoclasts derived from WT mice. Similar to the Pyk2 KO in vivo results, 
overall osteoclast apoptosis was more prevalent in the absence of Pyk2 in vitro, 
regardless of the number of nuclei. Also, osteoclasts derived from Pyk2 deficient mice 
did not exhibit the glucocorticoid pro-survival effects against alendronate-induced 
apoptosis of osteoclasts derived from WT mice. Similarly, osteoclasts treated with the 
Pyk2 kinase inhibitor (Figure 4-4C) derived from C57BL/6 mice were not protected from 
bisphosphonate-induced apoptosis by GC. Therefore, prevention of osteoclast apoptosis 
by GC requires Pyk2 kinase activity. Taken together, these pieces of evidence 
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demonstrate that the inherent osteoclast dysfunction conferred by lack of Pyk2 overrides 
GC induced resorption.  
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Discussion 
This study provides insights into novel mechanisms of glucocorticoid action and 
the cellular basis by which inactivation of Pyk2 signaling interferes with the detrimental 
skeletal effects of glucocorticoid excess in bone.   
The findings reported here demonstrate that Pyk2 is required for glucocorticoid-
induced bone loss and bone fragility in vivo as glucocorticoid stimulated cellular 
responses of increased osteoblast/osteocyte apoptosis and increased osteoclast-driven 
resorption, but not from the suppression of bone formation, are Pyk2 dependent.   
Pyk2 KO mice treated with glucocorticoids did not lose bone at any site as 
detected by DXA or exhibit the hallmark GC-induced thinning of cancellous bone. Pyk2 
deficiency also prevented bone fragility induced by glucocorticoids, which was mainly 
driven by bone loss as indicated by comparing reductions in ultimate force to the lack of 
reductions in ultimate stress that accounts for the amount of bone (BV/TV) and cross-
sectional area (Figure 4-1). This glucocorticoid mouse model also consistently (118) 
demonstrates the bone weakening effects of detrimental microarchitectural trabeculae 
thinning induced by glucocorticoids as indicated by reductions in both the energy to 
ultimate load and toughness mechanical properties.    
Consistent with previous in vitro reports (54), the current study’s in vivo results 
indicate that Pyk2 is required for glucocorticoid-induced apoptosis of osteocytes and 
osteoblasts. Unexpectedly, prevention of glucocorticoid-induced osteoblast apoptosis did 
not prevent reductions in bone formation as clearly indicated by circulating levels of 
P1NP and OCN as well as dynamic histomorphometric indexes (Figure 4-2). Reductions 
in P1NP levels were detected between Pyk2-/- and WT placebo treated 4 weeks after 
pellet implantation; however, the mechanism for this finding remains unknown. Further, 
no differences in circulating OCN levels were found between the genotypes at either 2 or 
4 weeks after pellet implantation. These findings are in contrast to previous reports of 
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increased BFR/BS, MAR, MS/BS with administration of Pyk2 inhibitor PF-431396 in an 
OVX rat model (115). However, glucocorticoids have several known mechanisms, such 
as suppression of OCN (33;34) and Col1A1 (35;36) expression, suppression of 
canonical WNT signaling via increased WNT antagonist Sost/sclerostin (118) or Dkk1 
(119;120) expression, and reductions of β-catenin/TCF/LEF transcription activity (55) to 
reduce bone formation that Pyk2 deficiency/inhibition would not be anticipated to alter. 
Consistent with the in vivo evidence, the synthetic glucocorticoid dexamethasone 
reduced mineral deposition of primary osteoblast cultures derived from Pyk2 KO mice or 
from C57BL/6 mice treated with a Pyk2 inhibitor (Figure 4-2). Therefore, the 
mechanisms of glucocorticoid inhibition of bone formation and mineral matrix production 
in osteoblasts occur independently of Pyk2 in vivo and in vitro.    
These studies also demonstrate in vivo that Pyk2 deficiency prevents 
glucocorticoid stimulated resorption as Pyk2 is required for normal osteoclast 
attachment, activity, and anti-apoptotic/survival signaling. Glucocorticoid treated mice 
exhibited increased resorption due to increased osteoclast numbers as indicated by 
elevation of circulating CTX and TRAP 5b levels as well as osteoclast number and 
surface (Figure 4-3).  However, resorption was not elevated in glucocorticoid treated 
Pyk2 KO mice as shown by a lack of increased CTX or osteoclast surface. Consistent 
with previous reports of defective podosome cell attachment and pit resorption of dentin 
coated slides in Pyk2 deficient osteoclasts in vitro (116), Pyk2 KO mice exhibited 
osteoclasts partially attached to bone surfaces (Figure 4-3F) as well as increased 
number of TRAPase positive multi-nucleated osteoclasts not attached to bone surfaces 
located in the bone marrow. While the marrow osteoclasts contributed to the elevation of 
circulating TRAP 5b levels in Pyk2 KO mice, the resorption activity and individual cell 
activity of these partially attached osteoclasts and marrow osteoclasts was diminished 
even in the presence of excessive glucocorticoid conditions as indicated by CTX and the 
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CTX/TRAP 5b ratio. Further, the lack of proper cell attached in Pyk2 KO osteoclasts 
treated with glucocorticoids led to a mismatch between the number of osteoclasts and 
osteoclast surface (Figure 4-3D).     
These findings also suggest a novel role for Pyk2 regarding osteoclast 
survival/anti-apoptotic signaling in vivo and in vitro, which also contributed to the 
inhibition of glucocorticoid stimulated resorption in Pyk2 KO mice.  An elevation of 
apoptotic osteoclasts both on the bone surface and in the marrow was exhibited by Pyk2 
deficient mice, and glucocorticoid administration did not reverse this apoptotic 
accumulation (Figure 4-4). Consistent with previous results (24), dexamethasone 
partially rescued bisphosphonate induced apoptosis of mature, fully differentiated 
osteoclasts derived from C57BL/6 or WT mice. However, the anti-apoptotic 
glucocorticoid effects did not occur in either Pyk2-/- derived osteoclasts or Pyk2 inhibitor 
treated osteoclasts derived from C57BL/6 mice in vitro. Taken together, these pieces of 
evidence indicate that the anti-apoptotic effects of glucocorticoids in osteoclasts are 
dependent on Pyk2 in vivo and in vitro. Thus, the impaired attachment, defective activity, 
and hindered anti-apoptotic signaling conferred by lack of Pyk2 in osteoclasts overrides 
glucocorticoid stimulated resorption.      
We conclude that Pyk2 deficiency protects from GC-induced 
osteoblast/osteocyte apoptosis and bone resorption to prevent bone loss. These findings 
provide a basis for therapies to target glucocorticoid-induce resorption.  
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Figure 4-1. Pyk2-/- mice are protected from bone loss and decreased bone strength 
induced by glucocorticoids. (A) BMD for WT or Pyk2-/- mice treated with placebo, 1.4 
mg/kg/day prednisolone (GC1), or 2.1 mg/kg/day prednisolone (GC2) for 28 days, 
measured by DXA. N=7-10. (B) Bone volume/tissue volume (BV/TV), trabecular 
thickness (Tb.Th.), separation (Tb.Sp.), and number (Tb.N.) of lumbar vertebrae L6 are 
shown. N=7-10. (C) Biomechanical properties were measured in vertebral bone (L6) by 
axial compression testing; N=7-10. Bars represent means ± SD. *p<0.05 vs. 
corresponding placebo-treated mice and #p<0.05 vs. placebo-treated WT mice, by two-
way ANOVA, Tukey post-hoc test. 
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Figure 4-2. Pyk2 deficiency protects from osteoblast and osteocyte apoptosis, but 
not suppression of bone formation or mineral deposition induced by GC. (A) 
Apoptosis of osteoblasts (Ob) and osteocytes (Ot) was quantified in cancellous and 
cortical bone in longitudinal sections of lumbar vertebrae (L1-L3) stained for TUNEL. 
N=3-4. P1NP, N=8-10 (B), and osteocalcin (OCN), N=6-7 (C) were measured in blood 
collected 2 or 4 weeks after pellet implantation. (D) Mineralizing bone surface per bone 
surface (MS/BS), mineral apposition rate (MAR), and bone formation rate per bone 
surface (BFR/BS) were quantified in longitudinal sections of lumbar vertebra (L1-L3). 
N=3-4. (E) Quantification of mineralization in cultures of calvaria-derived primary 
osteoblastic cells from WT or Pyk2-/- mice treated with vehicle (veh) or dexamethasone 
(dex) for 1 or 2 weeks stained using the OsteoImage Mineralization Assay Kit (RFU 
492nm/520nm excitation/emission fluorescence). Scale bars: 400 μm. N=7-8. (F) 
Mineralization quantification of calvaria-derived primary osteoblastic cell cultures from 
C57BL/6 mice treated with or without Pyk2 inhibitor PF-431396 with veh or dex for 10 
days stained using Alizarin Red S (405nm absorbance). N=4, measured in triplicate. 
Bars represent means ± SD. (A-D) *p<0.05 vs. corresponding placebo-treated mice and 
#p<0.05 vs. placebo-treated WT mice by two-way ANOVA, Tukey post-hoc test. (E-F) 
*p<0.05 vs. corresponding vehicle-treated cells and #p<0.05 vs. vehicle-treated cells 
from WT mice by two-way ANOVA, Tukey post-hoc test.  
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Figure 4-3. Pyk2 deficiency protects from GC-induced bone resorption and 
increased osteoclast surface. (A) CTX, N=6-7 (B) TRAP 5b, N=6-7 (C) CTX/TRAP 5b, 
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N= 5-6. were measured in blood collected 4 weeks after pellet implantation. (D) 
Osteoclast number (N.Oc/BS) and surface (Oc.S/BS) normalized to bone surface were 
measured and the percentage of marrow osteoclasts were determined in longitudinal 
sections of lumbar vertebra (L1-L3). N=6. (E) Representative microscopy images of 
osteoclasts on cancellous bone surface in lumbar vertebra (L2) stained for TRAPase. 
Scale bars: 25 μm. (F) Schematic and representative images of WT osteoclast, Pyk2 KO 
osteoclasts with impaired attachment, and Pyk2 KO marrow osteoclast. Bars represent 
means ± SD. *p<0.05 vs. corresponding placebo-treated mice and #p<0.05 vs. placebo-
treated WT mice by two-way ANOVA, Tukey post-hoc test. 
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Figure 4-4. Pyk2 deficient mice exhibit increased osteoclast apoptosis, which is 
not altered by GC, and GC prevention of osteoclast apoptosis requires Pyk2 
84 
kinase activity in vitro. (A) Apoptotic osteoclasts on bone surfaces and in the marrow 
were quantified in TRAPase and TUNEL double stained longitudinal sections of the 
distal femur. N=3. Representative microscopy images of osteoclasts on cancellous bone 
surface are shown. Scale bars: 20 μm. (B-C) Quantification of apoptosis of differentiated 
primary osteoclasts derived from C57BL/6 mice or Pyk2-/- and WT mice treated with and 
without alendronate and vehicle (veh) or dexamethasone (dex) for 24 hours using 
TRAPase and hematoxylin staining. Scale bars: 20 μm. N=6. Bars represent means ± 
SD. (A) *p<0.05 vs. corresponding placebo-treated mice and #p<0.05 vs. placebo-
treated WT mice by two-way ANOVA, Tukey post-hoc test. (B-C) *p<0.05 vs. 
corresponding vehicle-treated cells and #p<0.05 vs. corresponding alendronate-treated 
cells by two-way ANOVA, Tukey post-hoc test. 
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Chapter 5 
Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms 
upstream of E3 ubiquitin ligases 
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Introduction 
Excess of glucocorticoids is the third most common cause of bone loss, after 
aging and menopause, and the leading iatrogenic cause of osteoporosis (2). 
Immunosuppressant therapy with glucocorticoids is highly beneficial for a wide range of 
inflammatory conditions. However, glucocorticoid treatment has devastating effects on 
the musculoskeletal system, with bone fractures occurring in approximately 30-50% of 
long-term glucocorticoid-treated patients (2;10;22;27;114). Glucocorticoids induce bone 
loss, decrease bone formation, and cause trabecular and cortical bone thinning, leading 
to increased bone fragility. In addition, glucocorticoids induce loss of skeletal muscle 
mass and weakness of particularly muscles of the hip and shoulder girdle, which in turn 
increases the risk for falls. The combined effects on bone and muscle are largely 
responsible for the increased fracture risk with glucocorticoid excess.  
The debilitating effects of glucocorticoids in muscle are of rapid onset, detected 
as early as 7 days after initiation of their administration in humans (121;122). 
Glucocorticoids reduce sarcolemmal excitability, decrease serum levels of creatine 
kinase and myoglobin, decrease cross sectional area of type 1, 2A and 2B myofibers, 
and reduce the specific force (strength) of muscle fibers. Muscle atrophy induced by 
glucocorticoids is accompanied by suppression of protein synthesis with simultaneous 
increase in protein catabolism, leading to reduced myotube diameter (100;123). The 
formation of new myotubes is also impaired as glucocorticoids inhibit myogenesis by 
downregulating myogenin gene expression. Glucocorticoid-induced protein catabolism in 
skeletal muscle is associated with enhanced Forkhead Box O (FoxO)-dependent 
transcription of members of the protein degradation machinery, including the ubiquitin-
proteasome system of E3 ubiquitin ligases, the lysosomal system of cathepsins, and the 
calcium-dependent system of calpains (123;124). E3 ubiquitin ligases muscle atrophy F-
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box (MAFbx, also known as atrogin1) and muscle RING finger 1 (MuRF1, also known as 
TRIM63) are known regulators of glucocorticoid-induced muscle atrophy both in vivo and 
in vitro, as well as a number of other sarcopenia-inducing conditions including 
denervation, immobilization, disuse, diabetes, and renal failure (125-127). Mice lacking 
MuRF1 are partially protected from muscle loss induced by glucocorticoids, and muscle-
specific deletion of the glucocorticoid receptor prevents the increased atrophy gene 
expression and muscle loss induced by glucocorticoids (128-130). The ubiquitin ligase 
MUSA1 (muscle ubiquitin ligase of the SCF complex in atrophy-1, also known as 
Fbxo30) has also been associated with increased protein catabolism and reductions in 
total protein content in muscle models of denervation injury/disuse (131). However, the 
mechanisms by which glucocorticoids upregulate the expression of atrophy-related 
genes have not been described. In addition, it is not known whether reduction in bone 
mass induced by glucocorticoids is also accompanied by stimulation of atrophy-related 
genes.  
In this study, we demonstrate that excess of glucocorticoids increase the 
expression in bone in vivo and in osteoblasts and osteocytes in vitro of the traditionally 
considered muscle-specific E3 ligases atrogin1, MuRF1, and MUSA1. In addition, we 
show that glucocorticoids increase the expression of Notch ligands, receptors, and target 
genes in muscle, but not in bone. Furthermore, glucocorticoid-induced expression of 
atrophy-related genes and muscle cell atrophy were prevented by pharmacologic 
inhibition of the Notch pathway. These findings demonstrate that glucocorticoid-induced 
loss of bone and muscle mass is accompanied by increased expression of atrophy-
related genes, although the upstream mechanisms are tissue-specific. Moreover, our 
results identify the Notch signaling pathway as a potential therapeutic intervention to 
prevent skeletal muscle atrophy and weakness induced by glucocorticoids. Our study 
provides the mechanistic basis for combining therapies that target each tissue to treat 
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glucocorticoid-induced osteopenia and sarcopenia and offer new molecular approaches 
to prevent glucocorticoid-induced atrophy of the musculoskeletal system.   
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Materials and Methods 
Mice. Female 16-week-old C57BL/6 mice (n=10 per group) were randomized 
based on spinal BMD and allotted into 4 groups, and implanted subcutaneously with 
pellets containing placebo or prednisolone (2.1 mg/kg/day) (Innovative Research of 
America, Sarasota, FL, USA), for 14 or 28 days. There were no differences in total body 
weight between the groups before or at 14 or 28 days after pellet implantation. Bone 
fluorochrome labeling was performed by intraperitoneal injections of 0.6% calcein and 
1.0% alizarin red at 10 and 3 days before the end of the experiment, respectively (94). 
Analyses were performed in a blind fashion. 
Muscle weight and function. Muscles were weighted immediately after dissection. 
In vivo and ex vivo muscle function testing was performed in female 20-week-old 
C57BL/6 mice (n=10 per group) that were randomized based on spinal BMD and lean 
body mass and allotted into 2 groups: placebo-controls or prednisolone-treated animals 
for 28 days.  
In vivo muscle function was quantified using the 1305A Whole Mouse/Rat Test 
System, Aurora Scientific Inc., Aurora, ON, Canada (132). Mice were anesthetized with 
isoflurane, and the right leg was shaved and cleaned with alcohol. Then, mice were 
placed in supine position with the right ankle at 90 degrees of dorsiflexion and the leg 
positioned perpendicular to the foot pedal. Two sterile monopolar stimulated electrodes 
were inserted subcutaneously near the tibial nerve with one electrode medial to the 
nerve and the other lateral in the posterior hind limb musculature. Electrode placement 
and stimulation current were adjusted to achieve maximum twitch response and then 
increased to ~35mA for plantarflexion to ensure supramaximal stimulation of muscle 
fibers. Maximum isometric torque (N/m) was recorded for stimulation frequencies 
between 25 and 300Hz, with a pulse width of 0.2ms and train duration of 200ms. Data 
were recorded by the Dynamic Muscle Control/Data Acquisition (DMC) and Dynamic 
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Muscle Control Data Analysis (DMA) programs (Aurora Scientific Inc., Aurora, ON, 
Canada).  
Ex vivo muscle contractility of the extensor digitorum longus (EDL) and soleus 
muscles was performed as previously described (133). Briefly, muscles were dissected 
from the hind limbs while immersed in Ringer’s Solution consisting of 136.9mM NaCl, 
2.68mM KCl, 1.84mM CaCl2 dihydrate, 1.03mM MgCl2 hexahydrate, 5.55mM dextrose, 
11.91mM NaHCO3, and 0.44mM NaH2PO4 anhydrous at pH 7.4. Stainless-steel hooks 
were fastened to the tendons of the muscles using 4-0 silk sutures, and muscles were 
placed between a force transducer (Aurora Scientific Inc., Aurora, ON, Canada) and an 
adjustable hook. Muscles were then submerged in a stimulation chamber containing 
O2/CO2 (95/5%) bubbled in Ringer’s solution and placed between two platinum 
electrodes. Muscles were stimulated to contract by the electrodes, and the contraction 
data was recorded by the Dynamic Muscle Control/Data Acquisition (DMC) and Dynamic 
Muscle Control Data Analysis (DMA) programs (Aurora Scientific Inc., Aurora, ON, 
Canada). The muscle length was then adjusted to yield the maximum force before the 
initiation of force-frequency or fatigue stimulation regimens. The force-frequency 
stimulation regimen triggered contraction using incremental stimulation frequencies 
(0.5ms pulses at 1-150Hz for 350ms at supramaximal voltage of 1A). Between 
stimulations the muscle was allowed to rest for 1 minute for frequencies ranging 
between 1 and 70Hz, or for 3 minutes for frequencies ranging between 100 and 150Hz. 
For the force-frequency analysis, the specific force was calculated by dividing the 
absolute force by the whole muscle cross sectional area (CSA), which was calculated 
using the following equation: CSA (mm2) = mass (mg) / [(Lomm) x (L/Lo) x (1.06 
mg/mm3)], where Lomm is the optimal length, L/Lo is the fiber to muscle length ratio, and 
1.06 mg/mm3 is the density of muscle (134). L/Lo of 0.51 and 0.72 were used for the EDL 
and soleus muscles, respectively, following previous reports (135). The fatigue 
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stimulation regimen consisted of 50 or 150 repeated stimulation pulses for the EDL or 
soleus muscles respectively, at 70Hz occurring every 0.7 seconds. 
Study approval. All animal protocols were approved by the Institutional Animal 
Care and Use Committee at Indiana University School of Medicine, and animal care was 
carried out in accordance with institutional guidelines. 
Tissue and BMD measurements and micro-computed tomography (μCT) 
analysis. Mice anesthetized by inhalation of 1.7% isoflurane (Abbott Laboratories) mixed 
with O2 (1.5 liters/minute) were scanned using dual energy x-ray absorptiometry (DXA) 
with a PIXImus II densitometer (GE Medical Systems, Lunar Division, Madison, WI, 
USA) (94). BMD of the total body excluding the head and tail, the lumbar spine (L1-L6), 
and the femur, and lean body mass were quantified. Body weight and DXA 
measurements were performed 2-4 days prior to implantation (initial) and after 14 or 28 
days (final). Percent changes in body weight, lean body mass, and BMD were calculated 
with the following formula: [(final-initial)/initial] x 100. 
 For μCT analysis, bones were dissected, cleaned of soft tissue, and stored in 
70% ethanol until used. The distal femur and proximal tibia metaphysis was scanned at 
6μm resolution (Skyscan 1172; SkyScan, Aartselaar, Belgium). Measurements were 
done 60μm away from the growth plates, as described (93;94).  
Bone dynamic histomorphometry. Following μCT analysis, tibiae were then 
embedded in methyl methacrylate, and thick cross-sections at the mid-diaphysis were 
prepared using a diamond-embedded wire saw (Histosaw, Delaware Diamond Knives, 
Wilmington, DE, USA) and ground to a final thickness of 30–35µm for periosteal and 
endosteal bone formation measurements (136). Four µm-thick longitudinal sections of 
the proximal half of the tibia were also prepared for cancellous bone measurements. 
Fluorochrome labels were quantified using OsteoMeasure High Resolution Digital Video 
System (OsteoMetrics, Decatur, GA, USA) (137). To calculate bone formation rate 
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(BFR/BS) when only single labels were present, a value of 0.1µm/day was used for 
mineral apposition rate (MAR) (137;138). Terminology and units are those 
recommended by the Histomorphometry Nomenclature Committee of the ASBMR (139). 
Ex vivo bone and muscle organ cultures. Femoral and tibial long bones were 
harvested from C57BL/6 female and male mice, and marrow was flushed out using a 
sterile syringe. Bones were then maintained in α-MEM containing 10% FBS and 1% 
penicillin/streptomycin for 24 hours, followed by addition of 1μM dexamethasone or 
vehicle (ethanol), in the absence or presence of 5mM GSI XX, and cultured for an 
additional 6 hours. Tibialis anterior muscles were isolated from 1-month-old C57BL/6 
female and male mice and placed in 48-well plates. Muscles were rinsed with PBS and 
incubated in DMEM containing 10% FBS, 1% penicillin/streptomycin (Life Technologies 
Carlsbad, CA, USA) overnight. Media was replaced with DMEM + 10% FBS containing 
DMSO or 0.1µM GSI XX, together with vehicle or 1μM dexamethasone for 12 or 24 
hours. mRNA was isolated from bone and muscle samples to examine gene expression. 
Cell culture. Murine bone marrow derived OB-6 osteoblastic cells (61) and long 
bone-derived MLO-Y4 osteocytic cells (28) were cultured as previously published. 
Murine C2C12 myoblasts were purchased from ATCC and maintained at low confluence 
in DMEM medium containing high glucose, sodium pyruvate, 1% penicillin/streptomycin 
(Life Technologies Carlsbad, CA, USA), and 10% fetal bovine serum at 5% CO2. To 
induce differentiation, C2C12 cells were grown to confluency and then switched to 10% 
CO2 and 2% horse serum DMEM medium (140). After 72 hours, 1μM dexamethasone, 
0.03-0.1μM GSI XX, or this combination were added for 24 hours, and RNA was 
extracted to analyze gene expression, or cells were fixed for myotube diameter 
measurement.  
RNA extraction and qPCR. Total RNA was extracted using Trizol (Invitrogen, 
Carlsbad, CA, USA), and cDNA was synthesized with a high-capacity cDNA reverse 
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transcriptase kit (Applied Biosystems, Inc., Foster City, CA, USA). qPCR was performed 
as previously described (137). Relative mRNA expression levels were normalized to the 
housekeeping genes mitochondrial ribosomal protein S2 (Rplp2) or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) by using the ∆Ct method (93;137). All primers and 
probes were designed using the Assay Design Center (Roche Applied Science, 
Indianapolis, IN, USA) or were commercially available (Applied Biosystems, Inc., Foster 
City, CA, USA).  
Myotube diameter measurement. C2C12 myotube diameter was measured as 
previously published (140). Briefly, cells were fixed and permeabilized in ice cold 
acetone/methanol (1:1) at -20°C for 20 minutes, rehydrated for 10 minutes in PBS at 
room temperature. Subsequently, cells were incubated with an antibody against myosin 
heavy chain (Developmental Studies Hybridoma Bank, Iowa City, IA, USA) overnight at 
4°C with gentle agitation, followed by incubation with anti-mouse IgG labeled with green-
fluorescent Alexa Fluor 488 dye as secondary antibody (Life Technologies, Carlsbad, 
CA, USA), for 1 hour at room temperature and protected from light. Nuclei were stained 
with DAPI and the images captured on an Axio Observer.Z1 (Zeiss) microscope. 
Myotube diameter was measured using ImageJ analysis software (Wayne Rasband, 
U.S. National Institutes of Health). All treatment conditions were performed in triplicate. 
Statistical analysis. Data are expressed as means ± standard deviations (SD). 
Sample differences were evaluated using SigmaPlot 12.0 (Systat Software, Inc., San 
Jose, CA, USA). Differences between groups were detected by Student’s t-test or two-
way ANOVA followed by the Tukey post-hoc method. Force-frequency relationships of 
muscle contraction, both ex vivo absolute and specific force and in vivo plantarflexion 
torque, and fatigue curves were analyzed by mixed-model, two-way repeated-measures 
ANOVA followed by Tukey post-hoc tests. To determine potential differences in 
fatigability, ex vivo fatigue data were also analyzed with Ordinary Least Squares 
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regression on group mean data for each stimulation number. For both treatment groups 
(glucocorticoid and placebo), two regressions were calculated: one fit to the first 10% of 
the stimulations and one fit to the last 90% of the stimulations. Differences in slope 
between groups for the 10% data and the 90% data were compared by Student t-test, as 
previously reported (141-143). 
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Results 
Glucocorticoids induce atrophy in bone and muscle in vivo. Total BMD and total, 
femoral and spinal BMD were decreased by glucocorticoids after 14 or 28 days, 
respectively (Figure 5-1A). Trabecular thickness of cancellous bone of the distal femur 
and proximal tibia metaphysis were also reduced after 14 days (Figure 5-1B and C). 
Bone formation rate (BFR/BS) was suppressed by 14 days in the cancellous bone of the 
proximal tibia, as well as in the periosteal and endocortical surfaces of the tibia mid-
diaphysis (Figure 5-1C and D). The decrease in BFR/BS was the result of a decrease in 
mineral apposition rate (MAR) and of mineralizing surface (MS/BS) in all bone 
envelopes.  
Glucocorticoids also caused muscle atrophy, as measured by reductions in total 
lean mass, an index of skeletal muscle mass, after 14 or 28 days (Figure 5-2A). In 
addition, glucocorticoids decreased at both time points the mass of the tibialis anterior 
(Figure 5-2B and C) and extensor digitorum longus (EDL) muscles (Figure 5-2B and 
D), the latter composed mainly of fast-twitch fibers and known to be affected by 
glucocorticoids (144-146). The weight of the soleus muscle, mainly composed of slow-
twitch fibers and known to be more resistant to glucocorticoid-induced atrophy, was not 
affected after 14 days of glucocorticoid administration (Figure 5-2C); and at 28 days, 
soleus mass was minimally but significantly decreased in one experiment (Figure 5-2C), 
but not affected in another experiment (Figure 5-2D). In the experiment in which the 
soleus mass was not decreased, glucocorticoids still reduced the ex vivo contractility 
force generated by both EDL and soleus muscles in response to force frequency and 
fatigue electrode stimulation regimens (Figure 5-2D). Both EDL and soleus muscles 
from mice receiving glucocorticoids exhibited a reduction in absolute contraction force 
compared to muscles from mice receiving placebo, as quantified by the force frequency 
test (Figure 5-2D, middle panels). However, only soleus muscles from glucocorticoid-
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treated mice exhibited a reduced specific contraction force compared to placebo, 
whereas specific contraction forces exhibited by EDL muscles were not different 
between groups, indicating that the decreased absolute force displayed by the EDL 
muscles is driven by tissue loss. During fatigue testing, the contraction force decreases 
rapidly for the first 10% of stimulations and more slowly for the last 90% of stimulations, 
independently of muscle type or treatment. Both EDL and soleus muscles from 
glucocorticoid-treated mice exhibited lower contraction force compared to muscles from 
placebo-treated mice (Figure 5-2D, right panels). The EDL muscles fatigued at a lower 
rate in glucocorticoid-treated mice compared to placebo-treated mice in both regions of 
the curve, as demonstrated by statistically lower slope values of the regression lines 
compared by t-test (legend of Figure 5-2). In contrast, soleus muscles from 
glucocorticoid-treated mice fatigued at the same rates as placebo-treated mice in both 
the first 10% and last 90% of stimulations, as the slopes of regression lines were not 
statistically different between groups. The EDL muscles from glucocorticoid-treated mice 
reached their lowest contraction force sooner than the placebo treated mice 
(approximately at 40 versus 50 stimulations) (Figure 5-2D, right panels). In contrast, the 
soleus muscles from glucocorticoid-treated and placebo treated mice reached their 
lowest contraction force at the same stimulation number (approximately 120 
simulations). These results suggest that glucocorticoid affects differently the endurance 
of fast- versus slow-twitch muscles. 
 In addition, glucocorticoids reduced maximum plantarflexion torque assessed in 
vivo at 14 and 28 days of treatment (Figure 5-2E). This test reflects the combined 
strength of posterior compartment leg muscles (gastrocnemius, soleus, tibialis posterior, 
fibularis brevis and longus, flexor hallucis longus, flexor digitorum longus and plantaris 
muscles). Thus, prednisolone administration consistently induces muscle atrophy as well 
as muscle weakness in our murine model of glucocorticoid excess.  
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Glucocorticoids increase the expression of atrophy genes in bone and muscle in 
vivo and in vitro. Earlier evidence showed that muscle atrophy induced by injury or 
disuse is associated with increased expression of the E3 ubiquitin ligases atrogin1, 
MuRF1, and MUSA1 with the consequent increase in protein ubiquitination, proteasomal 
protein catabolism, and reductions in total protein content (125;131;147). Traditionally, 
atrogin1, MuRF1, and MUSA1 have been considered as selectively expressed in 
skeletal muscle. However, detectable levels of these transcripts were found also in bone 
at lower detection levels, with average Ct values of approximately 30 in bone, compared 
to 20-25 Ct values in tibialis anterior and soleus muscles. Glucocorticoids increased the 
expression of atrogin1 and MuRF1 after 14 or 28 days in both bone and the tibialis 
anterior muscle (Figure 5-3A). MUSA1 expression was also increased in bone and the 
tibialis anterior muscle from mice receiving prednisolone for 28 days. Consistent with the 
previously reported resistance to glucocorticoids of type I slow twitch muscle fibers 
(144;145), 14 days of glucocorticoid exposure did not increase atrophy gene mRNA 
expression in the slow-twitch dominated soleus muscle. However, after 28 days of 
glucocorticoid exposure MuRF1 expression levels were increased in the soleus. 
Glucocorticoids also increased atrophy gene expression in ex vivo bone organ cultures 
(Figure 5-3B), in osteoblastic OB-6 cells (Figure 5-3C) and osteocytic MLO-Y4 cells 
(Figure 5-3D) treated with the synthetic glucocorticoid dexamethasone. Furthermore, 
dexamethasone also increased the expression of atrogin1 and MuRF1 in C2C12 
cultured under non-differentiating (myoblasts) and differentiating (myotubes) conditions 
(Figure 5-3E). Overall, these results indicate that atrophy-related gene expression is 
increased by glucocorticoids in bone and muscle in vivo and in vitro.  
Glucocorticoids increase expression of Notch signaling pathway components in 
skeletal muscle, but not in bone. In vivo glucocorticoid administration to mice for 14 or 28 
days did not alter the levels of the Notch receptors 1-4, the Notch ligands Dll1 and Jag1, 
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or the Notch target genes Hey1 and Hes1 in bone (Figure 5-4A). In addition, 
dexamethasone decreased the expression of Notch ligand Dll1 and Notch target genes 
Hey1 and Hes1 without altering the levels of Notch receptors 1-4 in both femoral and 
tibial ex vivo bone organ cultures (Figure 5-4B). Notch ligand Jag1 mRNA levels were 
also decreased by dexamethasone in femoral bone organ cultures; however, Jag1 
expression was not affected in tibial organ cultures. Glucocorticoids also decreased the 
expression of most Notch receptors and ligands, with the exception of Notch 4 
expression in OB-6 cells, without altering the levels of the target gene Hey1 in either cell 
type (Figure 5-4C and D). The expression of the Notch target gene Hes1 was also 
lowered by dexamethasone in OB-6 and MLO-Y4 cells. Thus, overall glucocorticoids did 
not increase, and in some cases decreased, the expression of Notch signaling 
components in bone in vivo, ex vivo, or in vitro.  
In contrast, in vivo glucocorticoids increased the levels of Notch receptors, 
ligands, and target genes in the tibialis anterior at both 14 and 28 days (Figure 5-5A). 
Further, addition of dexamethasone for 12 or 24 hours increased the expression of 
multiple Notch target genes in ex vivo organ cultures of tibialis anterior (Figure 5-5B). 
Moreover, addition of the Notch signaling pharmacologic inhibitor GSI XX to muscle 
organ cultures effectively blocked both the increase in Notch target genes (Figure 5-5B) 
and the increase in atrogin1, MuRF1, and MUSA1 gene expression increased by 
dexamethasone (Figure 5-5C). In contrast, GSI XX did not prevent the increase in 
atrogin1 and MuRF1 in bone organ cultures. In addition, dexamethasone induced a 
~20% reduction in myotube diameter of C2C12 cells, which was also prevented by the 
GSI XX inhibitor (Figure 5-5D). These results suggest that upregulation of atrophy-
related genes and myotube atrophy induced by glucocorticoids is at least partially 
mediated by activation of the Notc signaling pathway in muscle, but not in bone.   
99 
Discussion 
The current study demonstrates that glucocorticoids activate different signaling 
pathways in bone and muscle that result in upregulation of atrophy-related E3 ubiquitin 
ligases and identifies the Notch signaling pathway as a potential target to prevent 
glucocorticoid-induced muscle atrophy (Figure 5-6).  
Our findings demonstrate that glucocorticoids increased the expression of 
several E3 ubiquitin ligases in both bone and muscle in vivo in the well-established 
model of glucocorticoid excess, in ex vivo bone and muscle organ cultures, and in vitro 
in osteoblastic and osteocytic cell lines, as well as in myoblasts and myotubes. To our 
knowledge, this is the first report of expression in bone of atrogin1, MuRF1, and MUSA1, 
heretofore considered muscle-specific atrophy genes, as well as their upregulation by 
glucocorticoids. The relevance of atrophy gene expression for the action of 
glucocorticoids in bone is unknown. However, earlier studies showed that genetic global 
deletion in mice of MuRF1 protects from the loss of bone induced by hind limb unloading 
(148). MuRF1 KO mice were also protected from the decrease in histomorphometric 
measures of bone formation and the increase in osteoclasts in this model (148). This 
evidence, together with our current findings, raises the possibility that upregulation of 
MuRF1, and potentially other atrophy-related genes, contribute to the reduced bone 
formation and increased bone resorption induced by glucocorticoids, and suggests that 
targeting the atrophy pathway could interfere with glucocorticoid action in bone. Future 
studies will be required to directly examine the role of atrophy-related genes in 
glucocorticoid-induced bone disease.  
Extensive evidence demonstrates that the C57BL/6 mouse model of 
glucocorticoid excess used in our study reproduces their deleterious effects on bone 
(26;41;118). In addition, we recently reported that glucocorticoids also decrease muscle 
mass in this model (118), and we now show that glucocorticoids decreased skeletal 
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muscle mass as early as after 14 days, quantified by lean body mass, as well as the 
mass of individual muscles, in particular those rich in fast-twitch fibers like the EDL. 
Importantly, muscles from glucocorticoid-treated mice exhibited decreased strength 
(force) quantified ex vivo by contractility tests of individual muscles and in vivo by 
measuring isometric plantarflexion torque generated by muscles of the posterior 
compartment of the leg. Remarkably, we detected decreased strength (specific force) in 
the slow-twitch soleus muscle in the absence of reduction of soleus mass, suggesting 
that glucocorticoids might alter muscle function in the absence of detectable tissue loss, 
at least in muscles traditionally considered resistant to glucocorticoids (144;145). In 
contrast, the reduction in strength in the EDL muscle can be explained by loss of muscle 
mass, as it is corrected by normalizing per tissue mass. The lower rate of fatigue 
detected in the fast-twitch EDL muscles treated with glucocorticoids compared to 
placebo-treated muscles is potentially explained by the fact that EDL muscles are mainly 
composed of the highly fatigable myosin-rich type 2 fibers, which are preferential targets 
of glucocorticoid-induced muscle atrophy (149;150). Therefore, glucocorticoid treatment 
might induce loss mainly of highly fatigable fibers and thus the remaining fibers fatigue 
more slowly in EDL muscles from animals treated with prednisolone. In contrast, slow-
twitch soleus muscles fatigue at the same rate in glucocorticoid- and placebo-treated 
mice despite reductions in overall strength induced by glucocorticoids, revealing another 
distinction between the effects of glucocorticoids depending on the muscle type. This 
effect may in part explain the proximal myopathy seen in patients with diseases of 
excess corticosteroid secretion and patients treated with pharmacological doses of 
corticosteroids. The current findings with the C57BL/6 mouse model of glucocorticoid 
excess are consistent with the previously reported reduction in muscle fiber specific 
force in humans treated with glucocorticoids (122). Importantly, the reduction in muscle 
mass correlated with increased expression of the atrophy genes. Future studies are 
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warranted to establish the role of E3 ubiquitin ligases in muscle weakness induced by 
glucocorticoids.   
Activation of the Notch signaling pathway has been shown to be required for 
expansion of the satellite cell population, a known critical event for skeletal muscle repair 
(151;152). In addition, Notch signaling inhibits myogenic differentiation of progenitor cells 
by decreasing MyoD and myogenin expression and by reducing MyoD activity 
(151;153;154). These findings support the notion that Notch signaling is crucial for 
maintaining the self-renewal capacity of muscle satellite cells. Our current study reveals 
a novel role of the Notch pathway in the frame of glucocorticoid excess, as it shows that 
the expression of components of this pathway was strikingly upregulated by 
glucocorticoids in skeletal muscle. Moreover, inhibition of Notch signaling with the 
gamma secretase inhibitor GSI XX blocked the upregulation of atrophy-related genes 
and prevented the reduction in C2C12 myotube diameter induced by glucocorticoids.  
In contrast to the effects of glucocorticoids on muscle, glucocorticoids did not 
increase the expression of components of the Notch pathway in our in vivo, ex vivo, or in 
vitro models of bone and osteoblastic/osteocytic cells. Earlier work showed transient 
increases in Notch1 and Notch2 gene expression in osteoblastic MC3T3 cells treated 
with cortisol (155). However, similar to our study, the expression Dll1 and Jag1 Notch 
ligands was not altered by cortisol treatment in this previous study. Therefore, we can 
conclude that glucocorticoids activates Notch signaling in muscle, but not in bone, to 
induce atrophy. The mechanism underlying the upregulation of atrophy genes by 
glucocorticoids in bone remains unknown. However, it is possible that FoxO transcription 
factors are involved. In muscle, FoxO family members (FoxO1, 3, and 4) regulate the 
expression of atrogin1, MuRF1, and MUSA1 and are required for the full atrophic 
response to several inducers of skeletal muscle wasting, including starvation/fasting, 
denervation, and chronic kidney disease (156-158). In bone, FoxOs are activated by and 
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are critical for the defense against oxidative stress (ROS) (159). In addition, at least part 
of the effects of glucocorticoids in bone are due to accumulation of ROS as well as to 
endoplasmic reticulum (ER) stress, and are abolished by ROS or ER stress inhibitors 
(41). Furthermore, activation of FoxO in osteoblasts by glucocorticoids is blocked by 
ROS inhibition (55). Moreover, FoxO-mediated transcription is favored over Wnt/β-
catenin transcription (55); and activation of Wnt/β-catenin signaling protects from 
glucocorticoid-induced osteoporosis (118). Future studies will be required to reveal the 
role of FoxOs in the upregulation of atrophy-related genes by glucocorticoids in bone.  
In conclusion, our study identifies atrophy-related E3 ubiquitin ligases as 
potential mediators of bone and muscle atrophy induced by excess of glucocorticoids 
and points towards the Notch signaling pathway as a novel target to prevent 
glucocorticoid-induced muscle atrophy. These findings provide the basis for combination 
therapy using inhibitors that target signaling upstream of atrophy-related genes in each 
tissue to prevent glucocorticoid-induced osteopenia and sarcopenia. 
  
103 
Acknowledgments 
I would like to thank Danielle Richardson, Meloney Cregor, Hannah M. Davis, Ernie Au, 
Kevin McAndrews, Dr. Teresa Zimmers, Dr. Jason Organ, Dr. Munro Peacock, Dr. Lilian 
I. Plotkin, and Dr. Teresita Bellido for these efforts led to a publication in the journal of 
Endocrinology (160). I would also like to thank Dr. Xiaolin Tu, Dr. Nicoletta Bivi, Kelly C. 
Biro, Alexandra F. Stachel, Jasmine Tzeggai, and Kali M. Kuhlenschmidt for their 
technical assistance; and Dr. Jesus Delgado-Calle for insightful discussions of the data. 
This research was supported by the National Institutes of Health (R01-AR059357 to 
T.B.; T32-AR065971 to A.Y.S.; and NHLBI T35 HL110854-01) and the Veterans 
Administration (1 I01 BX002104-01 to T.B.).  
  
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1. Glucocorticoids induce atrophy of bone and suppression of bone 
formation. Female C57BL/6 mice were implanted with pellets releasing 2.1 mg/kg/day 
of prednisolone or placebo and BMD was assessed 14 or 28 days later. (A) Percent 
change in BMD was measured by DXA and calculated utilizing initial scans performed 
before pellet implantation and final scans performed at the indicated time points. (B and 
C) Trabecular thickness was measured by μCT analysis at the distal femur (B) and 
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proximal tibia metaphysis (C). (C and D) Dynamic histomorphometric parameters on the 
cancellous bone of proximal tibia (C) and periosteal and endocortical surfaces of the 
tibia mid-diaphysis (D) were measured in mice treated for 14 days with placebo or 
prednisolone. Bars represent means ± SD. N=7-10. *p<0.05 vs. placebo-treated mice by 
Student’s t-test. 
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Figure 5-2. Glucocorticoids induce muscle loss and weakness. (A) Percent change 
whole body lean mass determined by DXA. (B) Scheme depicting the position of the 
muscles tibialis anterior (TA), extensor digitorum longus (EDL), and soleus (SOL) 
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relative to the tibia. (C) Wet weight of tibialis anterior and soleus muscles recorded 14 or 
28 days after pellet implantation. (D) Wet weight of EDL and soleus muscles and ex vivo 
contractility muscle function testing recorded 28 days after pellet implantation. (E) 
Muscle function testing performed in vivo 14 and 28 days after pellet implantation. Bars 
represent means ± SD. N=7-10 for A and C and N=8-10 for D and E. *p<0.05 vs. 
placebo by Student’s t-test for A-C and muscle weights in D. *p<0.05 vs. placebo by two-
factor, mixed-model repeated measures ANOVA followed by Tukey post-hoc method for 
muscle functionality tests in D and E. For the fatigue tests in D, regression line equations 
for EDL muscles were the following: for the first 10% of the stimulations, y = -0.5387x + 
22.784 (placebo) and y = -0.3549x + 17.033 (glucocorticoids), p<0.05 by t-test; and for 
the last 90% of the stimulations, y = -0.1601x + 20.474 (placebo) and y = -0.102x + 
15.181 (glucocorticoids), p<0.05 by t-test. Regression line equations for soleus muscles 
were the following: for the first 10% of the stimulations, y = -0.0658x + 11.72 (placebo) 
and y = -0.0641x + 9.2375 (glucocorticoids), not significant by t-test; and for the last 90% 
of the stimulations, y = -0.0102x + 10.778 (placebo) and y = -0.0097x + 8.2384 
(glucocorticoids), not significant by t-test.  
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Figure 5-3. Glucocorticoids promote the transcription of atrophy genes in vivo, ex 
vivo, and in vitro. (A) mRNA levels were quantified in vertebral bone L4 (bone), and TA 
and SOL muscle preparations. The transcripts were normalized to the levels of the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Bars 
represent means ± SD. N=5-7 for L4, N=8-10 for TA and SOL. *p<0.05 vs. placebo-
treated mice by Student’s t-test. (B) Gene expression in bones from C57BL/6 mice 
cultured with vehicle or 1μM dexamethasone for 6 hours. Bars represent means ± SD. 
N=9-12. *p<0.05 vs. vehicle-treated cells by Student’s t-test. (C) OB-6 osteoblastic cells 
and (D) MLO-Y4 osteocytic cells were treated with vehicle or 1μM dexamethasone for 24 
hours. RNA was extracted and atrogin1 and MuRF1 levels were quantified by qPCR. 
Bars represent means ± SD. N=5-6. *p<0.05 vs. vehicle-treated cells by Student’s t-test. 
(E) C2C12 myoblasts were kept in growing media or induced to differentiate into 
myotubes for 6 days. Cells were treated with vehicle or 1μM dexamethasone for 24 
hours, RNA was extracted and atrogin1 and MuRF1 levels were quantified by qPCR. 
The transcripts were normalized to the levels of the housekeeping GAPDH. Bars 
represent means ± SD. N=3 for myoblasts N=6 for myotubes. *p<0.05 vs. vehicle-treated 
cells by Student’s t-test.  
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Figure 5-4. Glucocorticoids do not induce Notch activation in bone in vivo, ex 
vivo, or in vitro. The expression of the indicated genes normalized to GAPDH was 
measured by qPCR in (A) bone preparations obtained from mice treated with placebo or 
prednisolone for 14 or 28 days, and (B) in bones from C57BL/6 mice cultured with 
vehicle or 1μM dexamethasone for 6 hours. Bars represent means ± SD. N=9-10 for (A) 
and N=10-12 for (B). *p<0.05 vs. placebo-treated mice or vehicle-treated bones by 
Student’s t-test. Gene expression was measured in (C) OB-6 osteoblastic or (D) MLO-
Y4 osteocytic cells treated with vehicle or 1μM dexamethasone for 24 hours. Bars 
represent means ± SD. N=5-6 for (C), and N=6 for (D). *p<0.05 vs. vehicle-treated cells 
by Student’s t-test. 
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Figure 5-5. Glucocorticoids increase the expression of Notch signaling pathway 
components in muscle, and Notch inhibitor GSI XX prevents glucocorticoid-
induced atrophy-related gene expression and reduction in myotube diameter. (A) 
The expression of the indicated genes normalized to GAPDH was measured by qPCR in 
TA muscles from mice treated with placebo or prednisolone for 14 or 28 days. Bars 
represent means ± SD. N=6. *p<0.05 vs. placebo-treated mice by Student’s t-test. (B-C) 
TA muscles or tibial bones were isolated from C57BL/6 mice and cultured with vehicle or 
1μM dexamethasone in the presence and in the absence of the Notch inhibitor GSI XX 
for 12 (B top row and C top row) or 24 (B bottom row) hours for TA and 6 hours for tibia 
(C bottom row). RNA was isolated and the levels of the indicated genes were measured 
by qPCR and normalized to Rplp2. Bars are mean ± SD. N=5-7. *p<0.05 vs. 
corresponding vehicle-treated muscles and #p<0.05 vs. vehicle-treated muscles in the 
absence of GSI XX by two-way ANOVA, Tukey post-hoc test. (D) C2C12 cells were 
differentiated into myotubes and treated with vehicle or 1μM dexamethasone in the 
absence or in the presence of the indicated concentrations of GSI XX. Myotube diameter 
was measured as indicated in the Materials and Methods section. Scale bars = 200μm. 
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Bars represent means ± SD. N=3. *p<0.05 vs. vehicle-treated cells by two-way ANOVA, 
Tukey post-hoc test. 
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Figure 5-6. Glucocorticoids induce bone and muscle atrophy by distinct tissue-
specific mechanisms upstream of atrogin1, MuRF1 and MUSA1. Glucocorticoids 
induce atrophy of both bone and muscle, although by different upstream mechanisms 
that converge in upregulation of atrophy-related E3 ubiquitin ligase genes atrogin1, 
MuRF1, and MUSA1.  
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Chapter 6 
Conclusions and Future Directions 
 Overall, these studies highlight the contribution of resorption to the early bone loss 
and fragility induced by GC. Interestingly, both the inhibition of Sost/sclerostin and Pyk2 
signaling prevented GC-stimulated resorption and effectively protected bone mass and 
strength, even without reversal of GC suppressive bone formation effects. However, the 
contribution of decreased bone formation and osteoblast/osteocyte viability is also 
significant during the early phase of GC treatment as salubrinal’s reversal of these 
effects also protected against bone loss in the low GC dose treated mice. Taking 
together, these pieces of evidence indicate that the bone cellular responses of GC 
stimulated resorption, osteoblast/osteocyte apoptosis, and decreased bone formation all 
mechanistically contribute to the rapid bone loss of 6-12% exhibited during the first year 
of GC therapy in patients (29;161).  
 While current anti-catabolic interventions prevent bone loss during the first year of 
GC therapy, these therapeutic options do not address the marked decrease in bone 
formation that characterizes chronic GC excess. After the first treatment year of GC 
therapy, patients exhibit up to 3-5% reductions in bone per consecutive year of 
continued treatment; however, currently there is a lack of long-term anabolic 
interventions (29). Since, the 28 day prednisolone mouse model consistently 
recapitulates the early GC resorption phase, as indicated by circulating CTX and TRAP 
5b levels as well as increases in osteoclast number and surface, prolonging the GC 
exposure in this model is necessary to access interventions for bone loss associated 
with long-term GC therapy. Previously, reports utilizing similar mouse models have 
indicated that the elevations in resorption circulating markers of CTX (162;163) and 
TRAP 5b (163) after 28 days are no longer elevated after 56 days of GC treatment 
(162;163). Therefore, future studies extending GC exposure to 56 days will be utilized to 
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investigate potential anabolic therapeutic agents during the low bone turnover phase of 
GC-induced bone loss. 
 Specifically, whether the interventions of ER stress alleviation, increased canonical 
Wnt signaling, or inhibition of Pyk2 signaling protects the skeleton in the context of long-
term GC exposure remains unanswered. In the absence of high GC resorption activity, 
salubrinal or guanabenz may more effectively protected from bone loss and fragility by 
promoting osteoblast/osteocyte viability and osteoblast matrix mineral production even in 
the presence of GC. Further, guanabenz more effectively reversed GC suppression of 
osteoblast activity in vitro; however, whether guanabenz’s effects translate to increased 
bone formation in vivo remains unanswered. Also, further investigation is needed to 
address whether increased canonical Wnt signaling could preserve bone anabolism 
during the chronic phase of GC-induced bone loss. The absence of Sost/sclerostin did 
not prevent GC inhibitory effects upon bone formation or the downregulation of anabolic 
β-catenin targets; however, given the vast number of Wnts and several pathway 
antagonists (84), it is more than likely that targeting other pathway components could 
promote bone anabolism even in the context of excessive GC.  
 The use of a Pyk2 inhibitor could also potentially promote bone formation during the 
chronic low bone turnover GC phase. While previous reports have shown an age-related 
loss of both the increased osteoblast surface and increased bone formation in the Pyk2 
KO mice after 10 weeks of age (116), in vivo use of a Pyk2 inhibitor could exhibit the 
anabolic benefits of Pyk2 deficiency without the time-related diminished effects 
depending upon dose and duration. Also, the Pyk2 inhibitor PF-431396 was previously 
reported to protect against decreased bone formation in an OVX rat model (115), and 
this inhibitor also increased matrix mineralization production of primary osteoblasts in 
our studies. Overall, future investigations are warranted to determine whether 
interventions of ER stress alleviation, increased Wnt/β-catenin signaling, or Pyk2 
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inhibition will preserve bone formation thus preventing the bone loss induced by chronic 
GC exposure.  
 There also is an unmet need for a therapeutic agent that simultaneously addresses 
the GC-induced loss of tissue mass and strength for both bone and skeletal muscle.  
Our subcutaneous prednisolone pellet implantation mouse model consistently exhibits 
glucocorticoid-induced osteopenia and sarcopenia, which provides an opportunity to 
investigate crosstalk between these tissues as well as potential interventions for the 
atrophy of both tissues. Interventions using either genetic deletion of atrophy gene(s) or 
use of proteasomal/Notch signaling inhibitors are warranted to determine the therapeutic 
potential for targeting E3 ligases involved in musculoskeletal atrophy by GC.  
Interestingly, the GC induced preferential increase in FoxO transcription over β-
catenin/TCF/LEF transcription occurs in cells of the osteoblastic and myogenic linage 
(55), indicating a potential for increased canonical Wnt signaling to benefit both tissues. 
Although sost/sclerostin deficiency did not translate into protection from GC-induced 
skeletal muscle atrophy, suggesting a lack of bone-to-muscle crosstalk, whether muscle-
to-bone crosstalk was involved in the low bone formation and increased 
osteoblast/osteocyte apoptosis exhibited in the GC treated Sost KO mice remains 
unknown. Another finding that merits further investigation is the discovery of GC atrophy 
distinctions between fast (EDL) and slow (SOL) twitch dominated muscles, which 
prompts the question of what mechanistic GC alterations are involved in the loss of 
strength without affecting muscle mass for the slow twitch dominated muscles.  Future 
experiments are required to identify interventions that simultaneously prevent bone and 
muscle atrophy as well as the crosstalk nature between these tissues under excessive 
GC conditions. 
 In closing, the current studies demonstrate that the deleterious effects of 
glucocorticoids on the skeleton are initially linked to robust resorption activity and that 
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inhibition of catabolic processes by Sost/sclerostin or Pyk2 deficiency is sufficient to 
prevent bone loss and fragility. However, given the long-term usage of GC therapy, 
future experiments are required for the identification and investigation of potential 
interventions to stimulate anabolic bone responses as well as prevent muscle atrophy.    
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